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ABSTRACT 
Our bodies are constantly exposed to various microorganisms and there is a constant 
battle between their survival and ours. Fortunately we are equipped with our immune 
system that takes remarkably good care of us, but when it fails we all know the 
consequences. This thesis work concentrates on innate immunity and the molecular 
mechanisms set in place to fight infections and to keep our bodies functional. More 
specifically, the focus is on germline-encoded receptors MARCO and SCARA5 
capable of recognizing and handling pathogen- or damage-associated molecular 
patterns (PAMPs and DAMPs). 
Macrophage receptor with a collagenous structure (MARCO) is a pattern 
recognition receptor (PRR) expressed by professional phagocytes, macrophages and 
dendritic cells, and participates in the clearance of bacteria and pollution particles. It is 
a trimeric molecule with a short N-terminal cytosolic domain, a single pass 
transmembrane domain followed by a large extracellular region with a spacer domain, a 
long collagenous domain, and C-terminal scavenger receptor cysteine-rich (SRCR) 
domain. In this study it was established that the C-terminal SRCR domain of MARCO 
is the main functional unit mediating both ligand binding and adhesion.  
We could show that a soluble form of MARCO binds bacteria cell wall 
components lipopolysaccharide and lipoteichoid acid. Utilizing the soluble protein we 
identified several hydrophobic peptides that bound to the SRCR domain of the receptor. 
The peptide sequences were identified as part of complement component C4b that 
functions as an opsonin once bound to the surface of bacteria. We could detect some 
binding of C4b to MARCO, but the peptide sequence was not involved in the binding. 
Another ligand, acetylated low-density lipoprotein (AcLDL), was also found to bind to 
the SRCR domain. With the help of mutational analysis and by solving the crystal 
structure of a monomeric and dimeric form of the SRCR domain to 1.78 and 1.77 Å, 
respectively, we could identify in more detail that a β-sheets structure with several 
positively charged arginines and a negative cluster residing in a long loop area of the 
structure were important for the ligand-binding functions. These areas affected also 
MARCO mediated adhesion to various surfaces. Based on the ion-binding site found in 
the long loop region, we were able to show that Ca2+ is needed for ligand binding. 
Other half of the thesis work focused on the physiological function of SCARA5, 
a MARCO related scavenger receptor having an additional α-helical coiled coil domain 
between the spacer domain and the collagenous domain. Similar to MARCO, SCARA5 
was found to promote cell adhesion and bind and internalize ligands such as bacteria 
and LPS. In contrast, we could only see limited binding of AcLDL, the knowledge of 
which we used in the mutational analysis made to map the ligand-binding region in the 
MARCO SRCR domain. Further, we utilized the strong cell adhesion for selection of 
stable cell lines without using antibiotics and were able to improve cell viability and 
handling of the cells in serum-free culture conditions during protein production. Our in 
vivo functional studies of SCARA5 revealed that in contrast to MARCO, the receptor is 
expressed by a vimentin and platelet-derived growth factor receptor α (PDGFRα) 
positive subpopulation of fibroblasts participating in immune related homeostasis. The 
homeostatic function was evident on the aging SCARA5 deficient mice that developed 
antinuclear antibodies and connective tissue related autoimmune disease-like symptoms 
with lymphoid cell accumulations in several organs, especially lung. 
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1 INTRODUCTION 
Even though our bodies are constantly exposed to pathogens such as bacteria, viruses, 
parasites, and fungi, infections are rare and even in the case of a severe illness we 
usually recover within a couple of weeks. This remarkable capacity to infection 
resistance is accomplished by our immune system (Janeway and Medzhitov, 2002). An 
effective barrier against most microorganisms is provided by anatomical and 
physiological barriers such as the external or internal epithelial surfaces of skin, 
respiratory tract mucosa, gastrointestinal mucosa, and reproductive mucosa; epithelial 
cells are held together with tight junctions and the microorganisms are eliminated by 
ciliary movements, low stomach pH, and excretions such as mucus and saliva. Further 
protection is provided through the interplay of specialized cells and other components 
of innate and adaptive immunity, parts of which will be reviewed briefly in the 
following chapters (Turvey and Broide, 2010). 
 
1.1 INNATE IMMUNITY 
Innate immunity is an evolutionarily ancient way of defending the organism and many 
of the components involved are present from mammals to plants and simple 
multicellular organisms (Hoffmann et al., 1999; Janeway and Medzhitov, 2002; 
Uthaisangsook et al., 2002). Innate immunity relies on the recognition of distinct 
molecular motifs, pathogen-associated molecular patterns (PAMP), such as microbial 
proteins, lipids, nucleic acids, and carbohydrates. The recognition is mediated mainly 
by complement, antimicrobial peptides, and specialized pattern recognition receptors 
(PRR) on effector cells (Bardoel and Strijp, 2011; Olive, 2012). Other soluble 
mediators (humoral components) such as C-reactive protein, lipopolysaccharide (LPS) 
binding protein, and collectins are also involved (Turvey and Broide, 2010). 
 
1.1.1 Antimicrobial peptides 
Antimicrobial peptides found throughout the eukaryotic kingdom function by direct 
recognition of microbial structures and next to instant killing of the bacteria, but require 
high local concentrations for efficient action (Bardoel and Strijp, 2011; Hoffmann et 
al., 1999). They vary in length from 5-60 amino acid residues, but are mostly cationic 
in nature. Most antimicrobial peptides adopt an antiparallel β-sheet structure with a 
possible α-helix held together by multiple disulfide bonds (Brogden, 2005; Hoffmann 
et al., 1999).  
 
1.1.2 Complement system 
Complement (C) system is composed of more than 40 soluble and membrane bound 
proteins that participate in the elimination of microorganisms, immune complexes, and 
apoptotic cells. Furthermore, they enhance and direct adaptive immunity through 
opsonization and leukocyte chemotaxis (Ricklin et al., 2010). There are three 
alternative pathways to activate the complement system but they all converge at one 
central step: the cleavage of complement component C3 (Figure 1). After C3 cleavage, 
the cascade continues and leads to the formation of a C5b-9 membrane attack complex 
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capable of lysing the target cell (Bardoel and Strijp, 2011). Recently it has been shown 
that even some proteases such as plasmin and thrombin can activate C3. Furthermore, 
under some conditions mannose-binding lectin (MBL) can directly activate C3 (Ricklin 
et al., 2010). 
 
 
 
Figure 1. Overview of the complement system. Complement is activated by either the classical, lectin, 
or alternative pathway. Classical pathway is activated after C1q (red) recognizes the bacterium either 
directly or through an antibody (dark blue) immune complex. The recognition leads to the cleavage of C4 
into C4a and C4b (yellow) by a C1 complex (C1q, C1r, and C1s). C4b is attached to the surface 
(opsonization) and binds C2, which in turn leads to generation of C2a, C2b (white) and C3 convertase 
(C4b2b, purple) capable of cleaving C3 (light blue). In the alternative pathway the hydrolysis of C3 can 
occur spontaneously. The mannose-binding lectin (MBL) pathway is activated by recognition of 
carbohydrate-containing structures (e.g. LPS) via MBLs (green) or ficolins (yellow), which are bound to 
MBL-associated serine proteases (MASPs) capable of creating the C3 convertase needed to cleave C3 
(Ricklin et al., 2010). The activation of C3 leads to the formation of a signaling molecule C3a and C3b, 
which is deposited on the target surface (opsonization). Opsonization marks the bacterium for 
phagocytosis, but the complement cascade continues by cleavage of C5. C5a attracts phagocytes while 
C5b is the first component of the membrane attack complex (C5b-9) capable of lysing bacteria (Bardoel 
and Strijp, 2011).  
 
1.1.3 Effector cells 
The main effector cells in innate immunity are phagocytes (macrophages, monocytes, 
dendritic cells, and neutrophils), which can kill the bacteria within minutes. However 
other hematopoetic cells such as mast cells, eosinophils, and natural killer (NK) cells 
are involved. Further assistance is provided by fibroblasts, endothelial cells, and 
epithelial cells (Turvey and Broide, 2010).  
Neutrophils are the most abundant (~60 % of all the leucocytes) and the most 
important phagocytes normally circulating in blood. Any hereditary defects in their 
function lead to life threatening infections.  Upon infection, they rapidly migrate to the 
site and kill the bacteria by releasing a combination of proteases, lipases, antimicrobial 
peptides, amidases, and highly reactive oxygen species (Bardoel and Strijp, 2011).  
Macrophages and dendritic cells (DC) are both derived from circulating 
monocytes and reside in most tissues surveying the environment for any foreign or 
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harmful antigens. Upon contact with macrophage receptors, antigens are ingested 
through phagocytosis and processed for antigen presentation on major 
histocompatibility complex (MHC) I and II molecules. After encountering the antigens 
(exogenous or endogenous), DCs rapidly migrate to local lymphoid tissue where the 
antigens are cross-presented to passing immature T4- and T8-lymphocytes causing 
them to differentiate. In contrast, macrophages are either recruited to the infection site 
or they exert their function locally at different sites i.e. peritoneal macrophages, 
alveolar macrophages, Kuppfer cells of the liver, marginal zone macrophages of the 
spleen, and others. Macrophages present the antigens to effector T4-lymphocytes, 
which have already encountered the antigens before (DC contact), and start producing 
cytokines and chemokines to support the inflammatory response (Janeway et al., 2001). 
Most other hematopoietic cell types involved in innate immune responses have 
more immunomodulatory roles and they excrete different substances e.g. antimicrobial 
peptides or histamine from mast cells that can either kill the bacteria or work as 
chemokines or cytokines (Janeway et al., 2001). NK cells are a specialized cell type 
circulating in the body. They constantly survey the expression level of MHC-I 
molecules normally expressed on all other cell types. If a cell shows abnormal 
expression of MHC-I molecules, NK cell can induce a direct destruction of the cell and 
elimination of the threat (Stanietsky and Mandelboim, 2010).  
The nonhematopoietic cells function also as immunomodulators. Most epithelial 
layers are covered by mucus containing a repertoire of antimicrobial agents. On the 
other hand, endothelial cells express upon induction a repertoire of membrane bound 
receptors (selectins, vascular cell adhesion molecule-1) facilitating the migration of 
other immune cells to the infection site (Szmitko et al., 2003). All these cell types, 
including fibroblasts, express MHC-I molecules and cluster of differentiation (CD)40, 
which is an important costimulatory molecule needed for the interaction with effector 
T4-lymphocytes (Vogel et al., 2004). Furthermore, a circulating fibroblasts population, 
fibrocytes, capable of antigen presentation has been identified (Bucala et al., 1994; 
Chesney et al., 1997). In addition, fibroblasts act as support cells and hold together the 
integrity of lymphoid organs and thereby support the differentiation of various 
leukocytes (Roozendaal and Mebius, 2011).  
 
1.2 ADAPTIVE IMMUNITY 
Adaptive immunity relies on B and T lymphocytes and as briefly mentioned earlier 
receive help from the molecules and cells involved in innate immunity. The strength of 
the system is the ability to generate specific receptors and antibodies that have the 
capacity to recognize virtually any antigen. Because of the specificity, the process 
eliminating the antigens takes much longer (up to 5 days) than the immune reactions 
described earlier as part of the innate immunity (minutes, hours). However, adaptive 
immunity has memory and antigens encountered for the second time are eliminated 
rapidly. As a drawback, there is a risk of developing receptors and antibodies 
recognizing self-proteins and autoimmunity (Turvey and Broide, 2010).    
 
1.2.1 T lymphocytes 
T lymphocytes are assisting adaptive immunity through cell-mediated responses. There 
are two main types of T cells, which differ in their mode of action. The cell populations 
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expressing a surface molecule CD4 are considered as helper T cells and upon activation 
assist macrophages to kill bacteria, support the production of antibodies, regulate 
tolerance against self-proteins, and confer memory. The activated CD8 positive T cells, 
also known as cytotoxic T cells, kill affected cells by inducing apoptosis (Janeway et 
al., 2001).   
 
1.2.1.1 T cell development and specificity 
 
Precursors of T lymphocytes originate from bone marrow and migrate into the thymus, 
where they first maturate either into CD4 or CD8 positive cells through a positive 
selection process. In this selection process, only cells expressing T-cell receptor (TCR) 
proteins capable of recognizing MHC molecules survive. The cells recognizing MHC-I 
and MHC-II molecules become CD8 and CD4 positive, respectively.  TCR receptor 
specificity is established by random gene segment rearrangements and is the key 
behind the recognition of virtually any ligand (Janeway et al., 2001; Sebzda et al., 
1999). 
At this stage the cells are still able to recognize both foreign and self-antigens, 
and therefore they undergo a negative selection process. During this process the cells 
are challenged with a variety of self-antigens. In order to avoid autoimmune reactions, 
the self-reacting cells are eliminated (Janeway et al., 2001; Sebzda et al., 1999). 
Once T cells have passed the selection processes, they exit the thymus as naïve T 
cells and start circulating in the blood. Once the naïve T cells encounter DCs presenting 
the antigen recognized by the TCR, they become activated, start dividing, and become 
effector T cells, which again circulate in the blood and assist macrophages and B cells 
presenting the same antigen (CD4 positive cells, MHC-II recognition) or kill the 
affected cells (CD8 positive cells, MHC-I recognition) (Janeway et al., 2001). 
 
1.2.2 B lymphocytes 
B lymphocytes are behind the humoral response of adaptive immunity through their 
ability to produce antibodies against virtually any antigen. Unlike T lymphocytes, B 
cells are also antigen presenting cells (MHC-II) and require assistance from helper T 
cells (CD4 positive) in order to become antibody-producing plasma cells (Janeway et 
al., 2001). 
 
1.2.2.1 B cell development and specificity 
 
Just like T lymphocytes, B lymphocytes originate in the bone marrow. Similar to T cell 
development, they go through a positive and negative selection process, but instead of 
migrating to the thymus they stay in the bone marrow. During the positive selection 
process B cell precursors go through gene fragment rearrangements resembling those 
happening to TCRs. This process ensures that the maturating B cells will express a vast 
number of functional B-cell receptors (BCR) on their surfaces. BCRs are membrane 
bound immunoglobulins (Ig), which determine the specificity of the plasma cell 
secreted antibodies (Ig). During the negative selection process, the newly formed 
immature B cells recognizing self-antigens are eliminated (Janeway et al., 2001; 
Monroe et al., 2003). 
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The immature B cells expressing BCR exit the bone marrow and start circulating 
in the blood. When they are presented with BCR specific antigens in secondary 
lymphoid organs, they become activated and start presenting the antigens on their MHC 
molecules. A second activation step is required from a CD4 positive effector T cell 
before the cell can become antibody producing plasma cell. Further, this interaction 
enables the B cells to produce different classes of immunoglobulins and undergo 
additional fine-tuning of the expressed antibody sequences in order to improve the 
affinity between antibody-antigen complexes (Janeway et al., 2001).   
 
1.2.3 Autoimmunity 
Autoimmune disorders are characterized by conditions where the immune system is 
activated to react against self-antigens. As indicated above, this process is usually 
regulated tightly by negative selection of self-reactive B and T cells during their 
development. However, not all the self-antigens are present in the environment of 
“schooling” and some self-reactive cells escape into the blood stream. Fortunately the 
effects of many of these cells are suppressed by the action of regulatory T cells (Tregs) 
(Tian et al., 2012). Additional protection is achieved by compartmentalization; many of 
these cells are reactive against intracellular or nuclear macromolecules and will 
therefore never become activated (Kamradt and Mitchison, 2001). Even though defects 
in the regulation of adaptive immunity play a major role in the development and 
maintenance of autoimmune diseases, innate immune responses contribute to the 
disease by different mechanisms. For example there is compelling evidence that 
excessive activation of complement leads to many different types of autoimmune 
diseases (Meri, 2007).  
Currently there are over 70 known chronic autoimmune/autoinflammatory 
diseases. Through genetic association studies some of the susceptibility genes have 
been identified, but in more than 60 % of the patients the cause is unknown. 
Identification of the gene defects is difficult, because many of the diseases are caused 
by multiple gene mutations. Furthermore, environmental factors play a major role in 
the disease development. This is evident, since in many cases only one of identical 
twins develops the disease, even though they share the genetic code (Doria et al., 2012).   
  
1.3 PATTERN RECOGNITION RECEPTORS 
As indicated above, the effector cells of innate immunity express a limited number of 
germline encoded pattern recognition receptors (PRRs) that recognize conserved 
structures on the pathogens (PAMPs) or danger-associated molecular patterns 
(DAMPs) including endogenous molecules released from e.g. dying cells after tissue 
damage (Olive, 2012). However, the concept of pattern recognition includes even 
soluble proteins such as MBL, other complement proteins (C3b, C4b), C-reactive 
protein, lung surfactant proteins (SP-A and SP-D), and other collectins. Furthermore, 
some of these receptors are found even on B and T cells (Janeway and Medzhitov, 
2002; Turvey and Broide, 2010). Finally, apart from recognizing the patterns, some of 
the PRRs are able to mediate the inflammatory responses by inducing signaling 
pathways leading to the production of cytokines and chemokines (Iida et al., 2001). 
Next, some of the different types of PRRs will be reviewed with special emphasis on 
class A scavenger receptors. 
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1.3.1 Secreted PRRs – Collectins 
Collectins are a group of PRRs consisting of an N-terminal cysteine-rich domain, a 
collagenous domain, an α-helical coiled-coil neck domain and a C-terminal C-type 
lectin-like domain. They form trimers through their collagenous and coiled-coil regions 
and further oligomerize through the N-terminal cysteine-rich domain into tetrameric or 
hexameric multimers illustrated by rotary shadow imaging (Hansen and Holmskov, 
1998). The group of soluble collectins in humans includes liver and lung derived MBL, 
SP-A, SP-D as well as liver and kidney collectins (CL-L1 and CL-K1, respectively). In 
addition, a number of other collectins have been identified in other organisms e.g. 
amphioxus expresses 66 different collectins. (Ohtani et al., 2012). 
Similar to the MBL function described as part of the complement system, all the 
members of collectins play a part in the innate immune system. They recognize 
carbohydrate structures on microorganisms in a Ca2+-dependent manner via their C-
type lectin-like domains. Once bound to the microorganisms, they are recognized and 
engulfed by opsonin receptors such as complement receptor 3 (CD11b/CD18) 
expressed on the phagocytes. There are several factors contributing to the number of 
microorganisms recognized by collectins. First, specificity and affinity toward different 
carbohydrates vary between the collectins (Kishore et al., 2006; Ohtani et al., 2012). 
Second, specificity is affected by spacing of the lectin domains in the oligomerized 
proteins; SP-D is 46 nm long while SP-A is only 20 nm long (Hansen and Holmskov, 
1998). Third, the oligomerization increases binding affinity; a single lectin domain can 
be eluted with 0.1 mM glucose in contrast to 20 mM glucose needed for the 
oligomerized form (Hoppe and Reid, 1994).  
 
1.3.2 Membrane bound signaling PRRs – Toll-like receptors (TLR) 
TLRs, named after the homologuos protein Toll found in Drosophila malanogaster, are 
type I membrane proteins responsible for translating the recognition of PAMPs or 
DAMPs into signals leading to the activation of immune system (Lemaitre et al., 1996). 
They interact with many other PRRs and mediate signaling between innate and 
adaptive immunity. TLRs are widely expressed in epithelial and endothelial cells as 
well as in macrophages, neutrophils, and dendritic cells. To date, thirteen mammalian 
TLRs have been identified, but only ten homologues are expressed in humans. As 
membrane proteins, they can be found either on the plasma membrane (TLRs 1, 2, 4, 5, 
6 and 11) or intracellular compartments (TLRs 3, 7, 8 and 9) (Kawai and Akira, 2011; 
West et al., 2006). They possess an extracellular ectodomain composed of 19 to 25 
leucine-rich repeats (LRR) responsible for the ligand-binding activity, a single 
transmembrane helix, and an intracellular signaling domain known as Toll/interleukin 
(IL)-1 receptor (TIR) domain (Pandey and Agrawal, 2006). Structural studies revealed 
that the ligand-binding LRR ectodomain adopts a horseshoe-like shape capable of 
dimerization. Indeed, the receptors functions either as homo- or heterodimers (Kang 
and Lee, 2011).   
Different TLRs are able to bind directly or indirectly to a vast number of DAMPs 
or PAMPs derived from viruses, bacteria, mycobacteria, fungi, or parasites. Briefly, 
different PAMPs include lipoproteins, double- and single-stranded ribonucleic acid 
(RNA), flagellin, LPS, and deoxyribonucleic acid (DNA) (Kawai and Akira, 2011). 
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More specifically, TLR1/2 heterodimers are able to bind triacyl lipopeptides while 
TLR2/TLR6 heterodimers recognize diacylated bacterial lipoproteins, lipoteichoic acid 
(LTA), and fungi. Homodimeric TLR2 binds to various bacterial, fungal or paracitic 
peptidoglycans and viral protein hemagglutinin. The intracellular TLR3 is the main 
receptor for viral double-stranded RNA while single-stranded RNA is the ligand for 
TLR7 and TLR8. TLR4 is the main receptor for LPS but requires the presence of an 
adaptor protein MD2 and CD14 for signal transduction. The ligand for TLR5 is 
flagellin. TLR9, on the other hand, is the receptor for bacterial DNA. TLR11 binds to 
parasitic profilin and an unknown ligand on uropathogenic bacteria (Olive, 2012; West 
et al., 2006). 
 After recognizing their cognate PAMPs, the TLR receptors dimerize and induce 
microbe specific signaling pathways through their intracellular TIR domains. The 
specificity depends on the recruitment of different adapter proteins with another TIR 
domain. There are five known adapters: myeloid differentiation factor primary-
response gene 88 (MyD88), TIR-domain-containing adapter inducing interferon β 
(TRIF), TIR-domain-containing adapter protein (TIRAP), TRIF-related adapter 
molecule (TRAM), and sterile-α and Armadillo motif containing protein (SARM). 
Through complex interactions, the signaling pathways culminate in the activation of 
NF-κB (nuclear regulatory factor) or interferon regulatory factors (IRFs), which in turn 
induce the production of different cytokines and chemokines (Kawai and Akira, 2011; 
Olive, 2012).  
 
1.3.3 Cytosolic signaling PRRs –Nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLR) 
The NLR family of proteins are cytosolic signaling molecules recognizing a wide array 
of bacterial ligands and DAMPs mainly associated with cell death. They were first 
discovered when NF-κB pathway induction was seen after infection with some invasive 
bacteria e.g. Shigella flexneri (Fritz et al., 2006). Currently there are 23 known NLRs in 
humans. All these proteins consist of C-terminal LRR domain implicated in ligand 
binding, a central nucleotide-binding site (NBS or NACHT), and an N-terminal 
protein-protein interaction domain composed of either CARD (caspase-activating and 
recruitment domain), PYD (pyrin domain) or BIR (baculovirus inhibitor of apoptosis 
protein repeat). Nod1 and Nod2 were the first identified NLR family members. They 
both recognize subunits of bacterial peptidoglycan and induce either the NF-κB 
signaling pathway or mitogen-activated protein kinases (MAPKs). Upon ligand 
binding, most other NLRs lead to the activation of caspase-1-activating 
inflammasomes. Caspase-1 signaling pathway leads either to the production of IL-1β 
and IL-18 or to cell death (Fritz et al., 2006; Olive, 2012).  
 
1.3.4 Endocytic PRRs – Mannose receptor 
Mannose receptor belongs to a C-type lectin-like receptor superfamily. Most of these 
receptors bind to carbohydrates in a Ca2+-dependent manner, but some have lost the 
ability to bind Ca2+ and bind non-carbohydrate ligands. Structurally these proteins vary 
from receptors with a single or multiple copies of lectin-like domains to membrane 
bound and soluble collectins described earlier (Zelensky and Gready, 2005). Mannose 
receptor is type I transmembrane receptor composed of N-terminal cysteine-rich 
  8 
domain followed by a single fibronectin type II domain (FNII), eight copies of C-type 
lectin-like domains, a transmembrane domain, and a short C-terminal cytoplasmic 
domain. It is expressed by most differentiated macrophages, lymphatic and sinusoidal 
endothelium, mesangial kidney cells, tracheal smooth muscle cells, and the epithelium 
of the retinal pigment (Pluddemann et al., 2006).  
As indicated by its name, mannose receptor binds several ligands bearing 
terminal mannose residues. More specifically, the ligands are terminal L-fucose, D-
mannose, D-N-acetylglucosamine, and D-galactose. Typical targets are various 
microorganisms, such as Candida albicans, Pneumocystis carnii, Leishmania 
donovani, Mycobacterium tuberculosis, and Klebsiella pneumoniae. Mammalian 
glycoproteins seldom have terminal mannose or N-acetylglucosamine residues 
commonly found in the surface of microorganisms explaining the recognition between 
self and non-self and a role in immunity (East and Isacke, 2002).  
 
1.3.5 Endocytic PRRs - Class A scavenger receptors 
Scavenger receptors are membrane bound PRRs originally defined by their ability to 
bind and endocytose modified low-density lipoproteins (LDL), such as oxidized and 
acetylated LDLs (OxLDL and AcLDL) (Brown and Goldstein, 1983). Initial studies 
concentrated on their role in atherosclerosis, but lately they have been recognized as 
multiligand receptors for a variety of artificial or natural polyanionic ligands as well as 
many microorganisms and apoptotic cells. Scavenger receptors are a diverse group of 
proteins classified in groups (A-H) based on their multidomain structures, but here only 
the Class A scavenger receptors will be reviewed. (Areschoug and Gordon, 2008). The 
general domain organisation of these receptors is shown in Figure 2. Briefly, they are 
all trimeric type II membrane proteins with a short N-terminal intracellular domain, a 
single pass transmembrane domain, a short spacer region followed by varying lengths 
of α-helical coiled-coil domains and/or collagenous domains, and an optional C-
terminal scavenger receptor cysteine-rich (SRCR) domain or a C-type lectin domain. 
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Figure 2. Domain structure of class A scavenger receptors. There are five members of class A 
scavenger receptors (SCARA1-5): scavenger receptor A (SR-A I, 454 amino acids (aa)), macrophage 
receptor with a collagenous structure (MARCO, 518 aa), cellular stress response (CSR, 606 aa), 
scavenger receptor with C-type lectin (SRCL I, 742 aa) and testis expressed scavenger receptor (Tesr, 
491 aa) (Elomaa et al., 1995; Han et al., 1998; Kodama et al., 1990; Nakamura et al., 2001; Sarraj et al., 
2005). Three of the receptors have splice variants (SR-A II, CSR2 and SRCL II). The receptors are 
composed of a short intracellular domain, a transmembrane domain, a spacer domain and various lengths 
of α-helical coiled-coil domains and collagenous domains. The C-terminus may or may not include an 
SRCR domain or a C-type lectin domain. The lengths of all the receptors depicted in the figure are based 
on the measurements made with negative staining and rotary shadowing microscopy for SR-A I (44 nm) 
and MARCO (80 nm) (Resnick et al., 1996; Sankala et al., 2002). 
 
1.3.5.1 Scavenger receptor A (SR-A, SCARA1) 
 
SR-A was the first member of class A scavenger receptors to be cloned. It is also the 
founding member of the SRCR domain superfamily of proteins (Freeman et al., 1990; 
Kodama et al., 1990). It is a trimeric 220-250 kDa protein constitutively expressed in 
most tissue macrophages, DCs, and certain endothelial cells (Peiser et al., 2002). It 
exists as two functional splice variants I and II, and an additional isoform III trapped 
within the endoplasmic reticulum that may have a dominant-negative regulatory 
function (Gough et al., 1998). As indicated in Figure 2, SR-A II lacks the C-terminal 
SRCR domain. Similarly, the III splice variant lacks the first half of the SRCR domain 
making it unable to fold properly. Despite the structural difference, both SR-A I and 
SR-A II have similar ligand-binding properties; binding studies with transfected cells 
have shown differential binding affinity, but the expression levels might have been 
different (Peiser et al., 2000; Peiser et al., 2006). However, a recent report indicates that 
the SRCR domain is a binding site for complement component iC3b (Goh et al., 2010). 
Otherwise, the ligand-binding region has been localized to a positively charged lysine-
rich region at the C-terminus of the collagenous domain. Positive charge is required, 
since most of the ligands identified thus far are polyanionic in nature (Doi et al., 1993). 
Electron microscopy and rotary shadowing of soluble SR-A I and SR-A II molecules 
suggest that the protein is around 44 nm long but it is flexible and can bend with angles 
ranging from 0o to 180o between the α-helical coiled-coil domain and the collagenous 
domain (Resnick et al., 1996). 
The first identified ligands for SR-A were modified LDL molecules often found 
in atherosclerotic plagues. Since then the role of SR-A in the development of 
atherosclerosis has been extensively studied. Indeed, SR-A expression was found in the 
foam cells of the plagues, and the sizes of the atherosclerotic lesions were smaller in 
apolipoprotein E (ApoE)/SR-A or LDL receptor/SR-A double deficient mice than in 
ApoE or LDLR single knockouts (Babaev et al., 2000; Sakaguchi et al., 1998; Suzuki 
et al., 1997). However, somewhat contradictory results have been reported since then 
(Makinen et al., 2010; Manning-Tobin et al., 2009; Moore et al., 2005). Nevertheless, 
other evidence suggests a role for SR-A in lipid metabolism; ApoA-I and ApoE were 
found to be ligands for SR-A and in vivo overexpression of SR-A affects the serum 
lipid levels (Gao et al., 2003; Neyen et al., 2009). 
The first indication that SR-A has a role in the host defense came when it was 
found to bind the lipid A moiety of LPS (Hampton et al., 1991). Since then it has been 
shown to bind LTA, bacterial CpG DNA, double-stranded RNA, and live Gram-
negative and Gram-positive bacteria such as Escherichia coli, Staphylococcus aureus 
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and Neisseria meningitides (Greenberg et al., 1996; Limmon et al., 2008; Peiser et al., 
2000; Peiser et al., 2002; Zhu et al., 2001). Studies made with SR-A deficient mice 
have demonstrated that SR-A confers protection against viral and bacterial infections 
such as herpes simplex virus 1 and Gram-positive bacteria Listeria monocytogenes, 
Staphylococcus aureus, and Streptococcus pneumoniae as well as Gram-negative 
bacteria Neisseria meningitides (Arredouani et al., 2006; Pluddemann et al., 2009; 
Suzuki et al., 1997; Thomas et al., 2000). In contrast, a recent study shows that SR-A 
deficient mice are more resistant to polymicrobial induced sepsis (Ozment et al., 2012). 
The discrepancy can maybe be explained by the differences in the experimental models 
and how they induce different signaling pathways; SR-A has been shown to interact 
with cell surface TLR4 and endosomal TLR3 and TLR9 as well as intracellular NLR 
receptors in a competitive manner, and depending on the ligand pattern different 
signaling pathways are activated (Mukhopadhyay et al., 2011; Ohnishi et al., 2011; 
Ozment et al., 2012; Yew et al., 2010).  
Additional studies have shown that SR-A may play a role in the development of 
Alzheimer’s disease, diabetes, systemic lupus erythematosus (SLE), and viral hepatitis 
suggesting a role in inducing different autoimmune disorders (Horiuchi et al., 2005). 
Indeed, SR-A deficient macrophages showed reduced uptake of apoptotic cells, SR-A 
is regulating antigen transfer from B cells to DCs, and SR-A deficient mice show 
differential progression of experimental autoimmune encephalomyelitis (EAE) (Levy-
Barazany and Frenkel, 2012; Platt et al., 1996; Raycroft et al., 2012). 
 
1.3.5.2 Macrophage receptor with a collagenous structure (MARCO, SCARA2)   
 
MARCO was the second class A scavenger receptor to be identified. Normally, its 
expression is restricted to the marginal zone macrophages of the spleen, macrophages 
of the medullary cord of lymph nodes, and peritoneal macrophages (Elomaa et al., 
1995). Strikingly, its expression is upregulated in most tissue macrophages upon 
bacterial infections (Elomaa et al., 1998; van der Laan et al., 1997). This induction 
seems to be dependent on TLRs (Chen et al., 2010; Doyle et al., 2004; Mukhopadhyay 
et al., 2004). Similar to SR-A, MARCO is a 210 kDa trimeric protein, but adopts a 
rigid, 80 nm long rod-like structure as evidenced by negative staining and rotary 
shadowing microscopy. Interestingly, some of the molecules oligomerize similar to 
what is seen for collectins (Hansen and Holmskov, 1998; Sankala et al., 2002). In 
contrast to SR-A, the ligand-binding domain in MARCO resides in the C-terminal 
SRCR domain. First, antibodies directed against the domain could block ligand binding 
(van der Laan et al., 1999). Second, deletion mutants of the human and mouse MARCO 
without the SRCR domain were unable to bind ligands (Brannstrom et al., 2002; 
Elomaa et al., 1998). Third, the mutant proteins without the domain were unable to 
induce the formation of lamellipodia-like structures and long dendritic processes typical 
for MARCO transfected cells (Pikkarainen et al., 1999). 
Induction of MARCO expression in most tissue macrophages after an infection 
suggests a role for this receptor in host defense. Indeed, MARCO was shown to bind 
E.coli and S. aureus, but not yeast (zymosan) (Elomaa et al., 1995). Furthermore, 
capturing of heat killed bacteria by marginal zone macrophages could be inhibited with 
antibodies directed against the SRCR domain (van der Laan et al., 1999). Other 
bacterial ligands include LPS and CpG DNA (Jozefowski et al., 2006; Sankala et al., 
2002). Functional in vivo studies have shown that MARCO deficient mice are more 
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susceptible to Streptococcus pneumoniae and Clostridium sordellii infections 
(Arredouani et al., 2004; Thelen et al., 2010). Furthermore, MARCO expression gives 
protection against Leismania major infection in CBA/J mice derived macrophages 
(Gomes et al., 2009). Paradoxically, MARCO deficient mice are more resistant to 
endotoxin (LPS) induced septic shock and influenza A virus pneumonia (Chen et al., 
2010; Ghosh et al., 2011). This may be explained by the differential induction of TLR4, 
TLR3 and NLR mediated signal transduction (Mukhopadhyay et al., 2011). 
In addition to typical host defense functions, alveolar macrophages expressing 
MARCO participate in other scavenging functions such as binding of unopsonized 
pollution particles, oxidized lipids, and uteroglobin-related protein 1 (UGRP1) secreted 
by Clara cells (Arredouani et al., 2005; Bin et al., 2003; Dahl et al., 2007; Palecanda et 
al., 1999). MARCO deficient mice are also more sensitive to ovalbumin/aerosol 
challenge mimicking allergic asthma (Arredouani et al., 2007). Further, in contrast to 
its human variant mouse MARCO shows avid binding to AcLDL (Elomaa et al., 1995; 
Elshourbagy et al., 2000). 
MARCO seems to play a role also in the development of some autoimmune 
diseases. It was shown that synovial fluid mononuclear cells from rheumatoid arthritis 
patients express high levels of MARCO (Seta et al., 2001). In addition, SLE patients 
generate autoreactive antibodies against MARCO leading to impaired apoptotic cell 
clearance, (Chen et al., 2011; McGaha et al., 2011; Rogers et al., 2009; Wermeling et 
al., 2007). 
 
1.3.5.3 Cellular stress response (CSR, SCARA3) 
 
CSR was cloned after its expression was shown to be upregulated in normal human 
fibroblasts in response to oxidative stress (UV irradiation or hydrogen peroxide). 
Pretreatment with antioxidants prevented the induction (Han et al., 1998). The receptor 
was localized to the endoplasmic reticulum, but a recent uptake study with negatively 
charged peptide complexes suggests, but does not confirm, that some of the receptors 
might come to the cell surface of HeLa cells (Ezzat et al., 2012). It was also shown that 
C-terminal residues 440-543 of CSR1 interact with cleavage and polyadenylation-
specific factor 3 (CPSF3), which converts heteronuclear RNA to mRNA. The 
interaction induces translocation of the complex from cell nucleus to cytosol and blocks 
the polyadenylation process. In this way, CSR is able to suppress tumor growth and 
induce apoptosis (Zhu et al., 2009). CSR has also been shown to have a role in ovarian 
cancer, reduce the growth of tumor cells in vitro and in xenograft tumors as well as 
inhibit the growth of prostate cancer cells by inducing apoptosis through interaction 
with X-linked inhibitor of apoptosis protein (XIAP); C-terminal residues 513-572 of 
the collagenous region are needed for the interaction (Bock et al., 2012; Yu et al., 2006; 
Zheng et al., 2012). 
 
1.3.5.4 Scavenger receptor with C-type lectin (SRCL, SCARA4) 
 
SRCL is also known as CL-P1, a collectin isolated from placenta (Ohtani et al., 2001). 
It could also be regarded as part of the C-type lectin superfamily, because of its C-
terminal lectin domain, but apart from that, the structure resembles that of the other 
class A scavenger receptors (Figure 2). The receptor is widely expressed by vascular 
endothelial cells. The human protein was also detected in alveolar macrophages and 
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trophoblasts (Nakamura et al., 2001; Ohtani et al., 2001; Selman et al., 2008). It is 
capable of binding and internalizing bacteria (Escherichia coli, Staphylococcus 
aureus), yeast (Saccharomeces cerevisiae), fungi as well as oxidized LDL, but not 
AcLDL. The uptake can be blocked with cytochalasin D, wortmannin, poly I, and 
dextran sulfate (Jang et al., 2009; Nakamura et al., 2001; Ohtani et al., 2001).  
Many of the ligands bind to the collagenous sequence, but the receptor contains 
also the C-type lectin domain that binds multiple ligands containing lewis(x) 
trisaccharides (Galβ1-4(Fucα1-3)GlcNAc). These ligands include leukocyte and tumor 
cell expressed proteins such as carcinoembryonic antigen (CEA), CEA-related cell 
adhesion molecule 1 (CEACAM1), carcinoma associated T antigen and Tn antigen as 
well as lactoferrin and matrix metalloproteinase-8 and -9 released from secondary 
granules of neutrophils (Coombs et al., 2005; Feinberg et al., 2007; Graham et al., 
2011; Samsen et al., 2010; Yoshida et al., 2003). 
 
1.3.5.5 Testis expressed scavenger receptor (Tesr, SCARA5) 
 
SCARA5 was first described as a highly expressed protein in the testis, hence the name 
Tesr. With in situ hybridization studies on embryonal samples additional expression 
was detected in the ovary, brain, eye, head, heart, neural arch, and cartilage primordium 
(Sarraj et al., 2005). Later real time PCR and in situ hybridization studies on adult 
mouse tissues revealed additional expression of SCARA5 in the epithelium of bladder, 
lung, trachea, and small intestine (Jiang et al., 2006). In contrast, we (paper IV) and 
others have shown that SCARA5 is mainly expressed by mesenchymal cells, more 
specifically a subpopulation of fibroblasts (DeWitte-Orr et al., 2010; Li et al., 2009).  
Regardless of the expression pattern, SCARA5 functions as a scavenger receptor 
and readily binds heat killed E.coli and S. aureus, but not zymosan or modified LDL 
(Jiang et al., 2006). SCARA5 is also able to bind and endocytose ferritin and 
haptoglobin-hemoglobin complexes suggesting a role in iron metabolism (Li et al., 
2009). Interestingly, in a genome-wide association study SCARA5 expression was 
associated with increased levels of coagulation Factor VIII in plasma and a patient with 
mild iron overload was found to have a R471H mutation in SCARA5 (Antoni et al., 
2011; Lee et al., 2012). In addition, two siRNA studies indicate, but do not confirm, 
that SCARA5 binds double-stranded viral RNA and negatively charged cell penetrating 
peptide complexes (DeWitte-Orr et al., 2010; Ezzat et al., 2012). It has also been 
suggested that SCARA5 acts as a tumor suppressor gene. The expression of SCARA5 
was downregulated in several tumor samples and tumor cell lines after promoter 
hypermethylation. Both in vitro and in vivo studies suggest that SCARA5 expression 
suppresses tumor cell growth, invasiveness, and reduces the number of metastases. The 
opposite was seen with reduced SCARA5 expression (Huang et al., 2010; Khamas et 
al., 2012; Yan et al., 2012).  
 
1.3.6 The SRCR superfamily 
SRCR domain is an ancient and highly conserved domain of ~110 residues first 
identified in SR-A (Freeman et al., 1990). Since then, the domain has been found in 
numerous either soluble or membrane bound proteins often associated with the innate 
immune system. Additional variation to the SRCR superfamily brings the fact that 
many of the proteins are multimeric and may contain single copies or tandem repeats of 
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the domain (Martinez et al., 2011; Resnick et al., 1996). The immunological role of this 
domain seems evident, since the purple sea urchin, Strongylocentrotus purpuratus, 
which lacks the adaptive immune system, contains 1,095 tentative SRCR domain 
copies distributed to 218 genes (Rast et al., 2006).  
Depending on the number and position of cysteine residues (6-8), as well as 
based on the exon-intron organization, the SRCR domains have been divided into two 
subclasses (A and B) (Freeman et al., 1990; Resnick et al., 1996; Sarrias et al., 2004). 
Structurally both of these subclasses adopt a similar globular fold with a curved β-sheet 
cradling a single α-helix (Garza-Garcia et al., 2008; Hohenester et al., 1999; 
Rodamilans et al., 2007).  
Despite the large number of proteins with SRCR domains, there are only a few 
examples where function has been assigned to this domain. As mentioned earlier, the 
SRCR domain of MARCO participates in ligand binding and is involved in the 
induction of morphological changes in the cells (Brannstrom et al., 2002; Elomaa et al., 
1998; Pikkarainen et al., 1999; van der Laan et al., 1999). Similarly, the SRCR domain 
of SR-AI was found to bind iC3b (Goh et al., 2010). Another example is the SRCR3 
domain of human lymphocyte cell surface receptor CD6 that interacts with the 
activated leukocyte-cell adhesion molecule (ALCAM/CD166) (Patel et al., 1995). Also, 
gp-340/DMBT1 (deleted in malignant tumors 1) that binds and agglutinates 
Streptococcus mutans and various other bacterial strains is able to do so through a 
peptide sequence QGRVEVLYRGSWGTVC included in eight of its 14 SRCR 
domains (Bikker et al., 2004; Bikker et al., 2002).  The SRCR domains of DMBT1 
contain even a second peptide sequence  DDSWDTNDANVVCRQLGA able to bind 
hydroxyapatite (Bikker et al., 2013).  Furthermore, the first SRCR domain in SPα, a 
soluble human glycoprotein expressed by several types of macrophages, binds to 
Escherichia coli and Staphylococcus aureus (Sarrias et al., 2005). 
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2 AIMS  
The overall aim of the investigations presented in this thesis was to study the structural 
and functional properties of class A scavenger receptors MARCO and SCARA5. In the 
first half of the thesis the aim was to study how MARCO and its functional SRCR 
domain is able to bind various ligands such as bacterial cell wall components LPS and 
LTA. The aim of the second half of the thesis was to get insight into the function of 
previously uncharacterized, structurally related protein SCARA5. 
 
2.1 SPECIFIC AIMS 
The   specific aims of this thesis project were to: 
 
1. Identify potential new ligands for MARCO using a phage display screen and 
to study the biochemical ligand-binding properties of MARCO with BIAcore. 
Furthermore, we wished to narrow down the ligand-binding region in the 
SRCR domain of MARCO. 
 
2. Gain insight into which amino acid residues are responsible for ligand binding 
in the SRCR domain of MARCO by determining the crystal structure of the 
domain. 
 
3. To explore the adhesion properties of SCARA5 and its potential for increasing 
recombinant protein production in mammalian cells by improving the cell 
viability and culture properties of the cells as well as making it easy to select 
cells with high expression. 
 
4. To characterize the expression pattern and in vivo function of the novel class 
A scavenger receptor SCARA5 by generating specific antibodies and a 
SCARA5 knockout mouse line.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  15 
3 METHODS 
The methods used in the included papers (I-IV) are described in detail in the respective 
Materials and Methods sections. 
 
Surface plasmon resonance [I]  
A biochemical method to measure the equilibrium dissociation constant (KD) of an 
analyte and its ligand.   
 
Production and purification of proteins [I-IV] 
Proteins were produced either in E. coli [I, IV] or in mammalian cells [I-IV]. 
Conventional chromatography methods (anion/cation exchange chromatography, size 
exclusion chromatography) [II], affinity tags (Glutathione S-transferase (GST), 
polyhistidine, strep) [I, III, IV] or self-generated antigen coupled affinity matrixes [I, 
IV] were used for purification. 
 
Generation of antibodies [I, IV] 
GST and SCARA5 specific polyclonal antibodies were generated by immunizing 
rabbits with different fragments of SCARA5 either as GST fusion proteins or with 
polyhistidine tag. 
  
Ligand-Binding studies [I, II, IV] 
Several ligand-binding studies were used. In some cases purified proteins (soluble 
MARCO, SRCR domain) were coated on surfaces and overlaid with different ligand 
solutions to study the binding (BIAcore, phage display) [I]. In other types of assays 
cells expressing the protein of interest (transfected Chinese hamster ovary (CHO) cells, 
primary cells) were incubated with the ligand solution (Fusion peptide, fluorescently 
labeled bacteria, LPS and AcLDL) [I, II, IV]. 
 
Isolation of primary cells [IV] 
Different immune cell populations were isolated with magnetic dynabeads coupled 
with cell-specific antibodies. Primary fibroblasts were isolated from a cell suspension 
from which the macrophages were removed with dynabeads. After overnight plating, 
only fibroblasts stay attached on the cell culture plastic. 
  
Western blotting [III, IV] 
A method to detect and determine the size of a protein electrophoresed on a gel 
separating proteins based on their molecular weight. The proteins on the gels were then 
transferred (blotted) to a membrane where the protein of interest was localized using 
specific antibodies against it. Here it was used to detect proteins in different tissue 
lysates [IV], different fibroblast/macrophage cell lines [IV], and transfected cells [III] 
  
Northern Blotting [IV] 
A method to detect and determine the size of a messenger RNA first size-fractionated 
on a gel and then blotted on a membrane. The RNA of interest was then localized using 
a labeled probe specific for the RNA molecule.  
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Southern Blotting [IV] 
A method to detect a specific genomic DNA fragment first size-fractionated on a gel 
and then blotted on a membrane. The DNA of interest was then localized using a 
labeled probe specific for the DNA molecule.  
 
Immunostaining [I-IV] 
Immunofluorescence stainings were made to detect either the cell-surface proteins [I, 
II, IV] or the total proteins on permeabilized cells with MARCO, SCARA5, F-actin or 
Crb2 specific antibodies and fluorescently labeled secondary antibodies [I-IV].  
 
Histology and immunohistochemistry [IV] 
Light microscopy was used to examine the histology of different organs of 
experimental animals on paraffin embedded tissue sections stained with SCARA5 
specific antibodies and/or hematoxylin and eosin. Several other cell type markers were 
similarly localized in the tissues with specific antibodies. Fresh frozen tissue sections 
were stained with SCARA5, CD31, PDGFRα, α-smooth muscle actin (ASMA), F4/80, 
CD11b, fibroblast specific protein (FSP), and vimentin to identify the cell type 
expressing SCARA5 and analyzed under fluorescence or confocal microscope. 
 
Flow cytometry or FACS (Fluorescence activated cell sorter) [III] 
A method to quantify different cell populations based on the cell shape, size, and 
expression of different molecules. Here the proportion of SCARA5 positive cells in the 
cell suspension before and after the selection step was analyzed. 
 
Crystallography [II] 
Hanging drop vapor diffusion method was used to crystallize the purified monomeric 
and dimeric SRCR domain of MARCO. After indexing, integration, and scaling of the 
x-ray diffraction data, the first structure solutions were generated by molecular 
replacement followed by several rounds of iterative model building and refinement. 
 
Chemical cross-linking [II] 
In order to determine the oligomerization state of purified SRCR domains of MARCO, 
the proteins were mixed with amine-to-amine reactive cross-linker 
dithiobis(succinimidyl propionate) (DSP) and analyzed on SDS-PAGE. 
   
Generation of recombinant protein producing cell lines [III, IV] 
In order to produce large quantities of functional mammalian proteins (different soluble 
forms of the extracellular part of SCARA5 and globular subdomains 1-3 (LN3G) of the 
mouse laminin α3 chain) HEK-293 EBNA cells were transfected with constructs 
expressing the protein of interest. When using a conventional selection method, the 
cells with incorporated constructs were selected based on the antibiotics resistance 
conferred by the expression construct [III, IV]. In paper III, a new method to select the 
cells based on the SCARA5 adhesion is described. 
 
Cell adhesion assay [II, III] 
Cell adhesion assay was performed on cells expressing normal MARCO and different 
mutants of the SRCR domain [II]. In these assays the cells were plated on surfaces 
coated with gelatin, polyinosinic acid (Poly I), or polylysine in media with or without 
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Ca2+ and Mg2+. All the cells adhere to polylysine while only MARCO expressing cells 
adhere to gelatin and poly I. The cells remaining on the surfaces after washes were 
quantified by F-actin staining. In the adhesion assays with SCARA5 expressing cells 
[III], the cells were plated on tissue culture plastic. Cells remaining on the plates after 
washes were quantified by crystal violet staining. In some assays the cells were treated 
with EDTA or poly I to block the adhesion through SCARA5.  
 
Generation of expression constructs [I-IV] 
Conventional molecular biology methods were used to clone constructs for expression 
of GST-phage peptide [I], MARCO SRCR domain mutants [I, II], LN3G-protein [III], 
green fluorescent protein (GFP) and SCARA5 for selection [III], intra and extracellular 
part of SCARA5 in bacteria and mammalian cells for antibody production and full 
length SCARA5 for binding assays [IV]. 
 
Phage display screen [I] 
A phage library solution was overlaid onto plates coated with soluble MARCO. The 
wells were washed and bound phages were used to infect competent K91kan E.coli. 
The procedure was repeated three additional times and finally randomly picked, phage-
infected E.coli clones were sequenced to identify the peptides displayed by the phages. 
 
Animals and animal experiments [IV] 
A SCARA5 gene knockout construct was designed so that the transmembrane domain 
of the protein was deleted. The construct was used to generate a chimeric SCARA5 
knockout mouse line. The mice were backcrossed to C57BL6 strain for 10 generations. 
Some SCARA5 knockout mice were mated with PDGFRα knock-in mice (B6.129S4-
Pdgfrαtm11(EGFP)Sor/J) to generate knockout mice with GFP protein expression in the 
nucleus of PDGFRα expressing cells. These mice were used to confirm the 
coexpression of SCARA5 and PDGFRα in certain fibroblasts. Material for histological 
analysis and different stainings as well as for isolation of primary cells was collected 
from mice with different ages. 
 
RT-PCR and qPCR [IV] 
Total RNA was isolated from different isolated immune cells and C3H 10T1/2 cell line. 
RT-PCR reaction was performed to produce a cDNA library from the RNA. Similar 
cDNA libraries generated from different tissues were purchased from BD Biosciences. 
The cDNA libraries were used in qPCR to detect the amount of different class A 
scavenger receptors (SCARA1 to 5) in the immune cells or to detect the presence of 
SCARA5 mRNA in different tissues. 
 
Ethical considerations [I-IV] 
All the experimental studies were conducted according to regulations related to 
handling of laboratory animals and approved by local ethical committees. 
 
Statistical analysis [III] 
Data were analyzed either with student t-test. 
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4 RESULTS  
Following the initial cloning of class A scavenger receptor MARCO (SCARA2) 
(Elomaa et al., 1995), several studies have shown that MARCO is a pattern recognition 
molecule recognizing various ligands ranging from modified/unmodified self-
molecules to environmental particles and different bacteria and their cell wall 
components. The broad ligand repertoire can be seen as an indication of MARCO’s 
role in tissue homeostasis and as a molecule involved in innate immunity and defense 
against bacterial infections (Arredouani et al., 2004; Bin et al., 2003; Elomaa et al., 
1995; Gordon, 2002; Krieger and Herz, 1994). In the present thesis project, further 
evidence was provided on ligand-binding kinetics as well as the mode of binding to the 
C-terminal SRCR domain of MARCO (Papers I and II). 
While the role of the SRCR domain in MARCO’s ligand-binding function was 
studied, we identified a structurally similar previously unknown protein SCARA5 using 
mining of publicly available genome sequences. Our initial ligand-binding studies with 
SCARA5 showed that similar to MARCO, the novel receptor was able to bind bacteria. 
However, SCARA5 exhibited very low affinity to AcLDL. This notion was used as a 
tool to further study the function of MARCO SRCR domain (Papers I and II).  
To gain more understanding of the functional differences and similarities of 
MARCO and SCARA5, a mouse line deficient for the Scara5 gene was generated. By 
using this mouse model, SCARA5’s tissue expression pattern and its role in tissue 
homeostasis and development of a connective tissue disease resembling some 
autoimmune diseases seen in humans was elucidated (Paper IV). As SCARA5 
expression was found to be restricted to a subpopulation of fibroblasts and we had 
made a notion that similar to MARCO (Papers II and IV), SCARA5 adheres strongly to 
surfaces coated with gelatin, SCARA5 expression was used to improve the cell culture 
properties and protein production in mammalian cells (Paper III). 
 
4.1 THE ROLE OF MARCO SRCR DOMAIN IN LIGAND-BINDING 
ELUCIDATED BY PHAGE DISPLAY SCREENING AND ACETYLATED 
LDL BINDING (PAPER I) 
Evidence that MARCO SRCR domain has a functional role was observed when cells 
transfected with a truncated form of MARCO lacking the SRCR domain failed to 
induce typical morphological changes (Pikkarainen et al., 1999) and exhibited very low 
bacteria binding as compared to the full length MARCO (Brannstrom et al., 2002). In 
order to further study the ligand binding to MARCO, a mammalian expression system 
to produce soluble forms of the whole extracellular region of MARCO (sMARCO) as 
well as the SRCR domain was established. It was shown that functional proteins were 
generated and binding of bacteria and LPS could be detected in surfaces coated with 
sMARCO (Sankala et al., 2002). In Paper I, we sought to further characterize the 
biochemical binding properties of various ligands to sMARCO as well as identify 
possible new ligands with the help of a phage display screen. 
First, a surface plasmon resonance (BIAcore) based system to study the ligand 
binding to sMARCO was established. We could show avid binding of both Gram-
positive and -negative bacteria cell wall components LTA and LPS. Even stronger 
binding could be seen for another polyanionic molecule poly I, which is often used as a 
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blocking reagent when studying the function of scavenger receptors. Most of the 
identified ligands binding to scavenger receptors are polyanionic in nature (Gordon, 
2002). However, negative charge is not the only attribute behind binding, since no 
binding to sMARCO was detected with heparin.  
Next, a phage display screen was performed with sMARCO to identify possible 
new ligands that could be studied on BIAcore. After several rounds of screening, five 
peptide sequences were obtained, out of which two showed clear prevalence. Only 
these two peptides, VRWGSFFAAWL and RLNWAWWLSY, were studied further. 
Indeed, the VRWGSFFAAWL peptide showed strong binding to sMARCO also in a 
BIAcore setting. Unexpectedly, instead of being anionic in nature both of the peptides 
were composed of mostly hydrophobic residues.  
In the next set of experiments, the phage-peptide binding site in MARCO was 
localized to the SRCR domain. First, no binding of either of the phage-peptides could 
be detected on transfected cells expressing on their cell surface a truncated form of 
MARCO lacking the SRCR domain. In contrast, cells expressing a full-length MARCO 
showed avid binding. Second, this result could be confirmed by overlaying SRCR 
domain, sMARCO, control proteins BSA and recombinant Nephrin coated plates with 
the VRWGSFFAAWL phage. Only wells with the SRCR domain and sMARCO 
showed any binding. All the studies described above were conducted with the phage 
peptides. However, similar results were obtained when the experiments were conducted 
with a recombinant GST coupled fusion peptide or a synthetic peptide. Furthermore, 
these additional tests suggested that both peptides bind to the same site in the SRCR 
domain. However, the first 17 residues extending to the SRCR domain were not 
sufficient to restore binding to the peptide even though such a protein showed avid 
binding to bacteria (Brannstrom et al., 2002).  
In one set of the experiments, the human version of MARCO was found to bind 
the GST-peptide; the amino acid sequence identity between the human and mouse 
SRCR domains is 78 %. In contrast, there was no binding to full-length SCARA5. The 
SRCR domain of SCARA5 shares 45 % sequence identity with MARCO’s SRCR 
domain (Figure 3). However, when the SRCR domain of SCARA5 was totally or 
partially replaced by sequences of MARCO SRCR domain, an IW mutant with 
MARCO residues 423-481 and NC mutant with residues 423-507, the mutated 
SCARA5 protein was able to bind the GST-peptide fusion protein. This indicates that 
the peptide-binding site of MARCO SRCR domain resides within the sequence 423-
481 (Figure 3).  
 
 
 
Figure 3. Amino acid sequence alignment of MARCO and SCARA5 SRCR domains. The mouse 
sequences were aligned with the BLAST program at NCBI database http://www.ncbi.nlm.nih.gov/. The 
sequences showed 45 % sequence identity. The amino acid residues from the MARCO sequence included 
in an IW mutant of SCARA5 are underlined with black line. In a similar fashion, red line denotes the 
amino acid residues mutated in an NC mutant. 
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As mentioned earlier, we found that intact SCARA5 binds AcLDL very poorly. 
Therefore, we also tested the SCARA5 mutants with the whole MARCO SRCR 
domain and fragments of MARCO (IW and NC mutants) for AcLDL binding. Yet 
again, we could proof that the MARCO SRCR domain is important for ligand-binding, 
since the mutant with an intact MARCO SRCR domain bound strongly to AcLDL 
(Figure 4). Interestingly, the two latter mutants IW and NC were unable to bind AcLDL 
indicating that the last 11 residues of MARCO are required for the binding (Figure 3). 
However, AcLDL seems to bind to a different location on MARCO SRCR domain than 
the isolated phage peptide. The SRCR domain of SR-AI had previously not been shown 
to have any function, but when we tested it in a similar manner, we could see avid 
binding (unpublished data, Figure 4). 
 
 
 
Figure 4. Binding of AcLDL to cells expressing SCARA5 and its variants with SRCR domains 
from MARCO and SR-AI. CHO cells were transiently transfected with a control plasmid and plasmids 
expressing full-length SCARA5 and mutants with SRCR domains from MARCO or SR-AI. The binding 
of AcLDL (white dots) to these cells was tested. Top row, control cells and SCARA5 transfected cells 
exhibit hardly any binding of AcLDL whereas avid binding can be detected on cells expressing SCARA5 
mutants with MARCO and SR-AI SRCR domain. Bottom row, the transfection efficiency and protein 
expression was confirmed by immunostaining of the cells with antibodies recognizing the intracellular 
part of SCARA5. 
 
The purpose of the phage display screen was to search for new potential MARCO 
ligands. Interestingly, when the sequences of the identified peptides were used to screen 
protein databases, the closest sequence match could be found in the complement 
component C4. When the interaction between C4 and MARCO was tested, we could 
detect weak binding of C4b and C4d to sMARCO and cells expressing full-length 
MARCO. However, the binding could not be blocked by the GST-peptide 
demonstrating that if the interaction is true, C4 fragments and the peptide bind to 
distinct sites on MARCO. Furthermore, tissue-staining attempts to find endogenous 
ligands with antibodies recognizing the peptide sequence were made to no avail. 
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4.2 CRYSTAL STRUCTURE REVEALS MULTIPLE BINDING SITES IN 
THE MARCO SRCR DOMAIN (PAPER II) 
As was evident from previous studies, most identified ligands of mouse MARCO bind 
to the SRCR domain (Brannstrom et al., 2002; Chen et al., 2006; Pikkarainen et al., 
1999; Sankala et al., 2002). In order to gain better understanding of the ligand-binding 
properties of the domain we sought to solve the crystal structure of the domain. The 
protein was produced using previously established mammalian cells stably expressing 
the mouse MARCO SRCR domain starting from the amino acid residue Q421 (Figure 
3) (Sankala et al., 2002). The protein contained no purification tags and therefore the 
purification was achieved using conventional ion-exchange and size exclusion 
chromatography methods. Based on the size exclusion chromatography and chemical 
cross-linking studies, the protein could be purified in a monomeric and dimeric form 
(Figure 5). 
 
 
Figure 5. Chemical cross-linking of different forms of purified MARCO SRCR domains. The 
MARCO SRCR domain could be separated in two distinct pools during anion exchange chromatography. 
These pools had different retention times on the size exclusion chromatography indicating the presence of 
monomeric and dimeric forms of the protein. This could be confirmed when the proteins were chemically 
cross-linked with amine reactive dithiobis(succinimidyl propionate) (DSP) and size-separated on an SDS-
PAGE gel. The sample order in the silver stained gel is indicated above the gel. Based on the molecular 
weight standard sizes, the protein was purified as monomer and dimer. The expected molecular weight of 
a monomeric MARCO SRCR domain is 11 kDa. 
  
The purified proteins were crystallized using a hanging drop vapor diffusion 
method. After some optimization, good quality crystals were obtained and used to 
collect diffraction data (Figure 6). Relatively good quality data was collected up to 1.78 
Å and 1.77Å for the monomeric and dimeric forms of the SRCR domain, respectively. 
Both structures were solved by molecular replacement and after the final refinement 
both structures had good stereochemistry and the R-factors were within acceptable 
range indicating that the structures were correct.    
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Figure 6. Crystallization of the monomeric and dimeric form of MARCO SRCR domain. After 
optimization of the crystallization conditions, monoclinic crystals were obtained of the monomeric form 
of the protein (upper panel). The crystals of the dimeric form showed triclinic appearance (lower panel). 
 
The monomeric MARCO SRCR domain structure has a compact globular fold 
(~30 Å in diameter) with a single α-helix wrapped from one side by a twisted β-sheet 
composed of six (A-F) antiparallel β-strands and a long loop arching over to the other 
side. Two disulfide bonds stabilize the long loop region. A third disulfide bond is 
connecting the C-terminal end of the protein to the α-helix. The β-strands A-C in the 
N-terminus are held in place mainly by hydrophobic contacts. Two Mg2+ ions were 
modeled into the structure (Figure 7 A-B). 
The dimeric form of the purified MARCO SRCR domain was relatively stable, 
but it dissociated in solutions containing trace amounts of nonpolar solvents. This 
phenomenon could be explained by the dimeric structure that formed through β-strand 
swapping of the first N-terminal β-strands (A) in each monomeric domain structure. 
Strikingly, a large (~26 x 15 Å) eight-stranded antiparallel β-sheet is formed due to the 
β-strands swapping. The dimer had three bound sulfate ions in the structure (Figure 
7C). 
 
Figure 7. Monomeric and dimeric structures of the MARCO SRCR domain. A and B, the 
monomeric structure is presented in two different orientations. The β-strands A-F are presented in green, 
helices are colored in pink. Disulfide bonds are shown in yellow. Two bound Mg2+ ions are shown as 
blue spheres. C, a similar representation of the dimeric structure. Three sulfate ions are shown in yellow-
red.  
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In order to detect putative domain motions, the monomeric structure coordinates 
were submitted to the Dynamite server (Barrett et al., 2004), which returned possible 
modes of dynamics. The covariance lines presented in Figure 8A highlight regions that 
will move together. From the stereo image it can be seen that the β-turns AB and BC, 
the end of the α-helix together with the β-strands D and F as well as the long loop 
region move as separate units. The porcupine stereo image seen in Figure 8B shows the 
direction and magnitude of the movements.  
 
 
Figure 8. Stereo representation of possible modes of molecular movements in the monomeric 
MARCO SRCR domain structure. A, a stereo image of the monomeric MARCO SRCR domain with 
covariance lines (red) highlighting the regions that move together. B, porcupine representation of the 
principal motion in stereo.  Each cone (blue) renders the magnitude and direction of the motion.    
 
Since the ligands that bind to scavenger receptors generally are anionic in nature, 
we expected to find positively charged regions in the surface of the structure. Indeed, 
the surfaces around the β-sheet structures in both the monomeric and dimeric structures 
have clearly a positive electrostatic potential. The area is especially prominent in the 
dimeric structure. Importantly, this region contains three linear RXR motifs and two 
structural RER motifs that have previously been shown to be important for bacteria 
binding (Brannstrom et al., 2002). To our surprise, a roughly as large negative cluster 
(~20 x 20 Å) as the positive cluster was found in the structure. The cluster is located on 
the opposite end of the molecule at the long loop area. Some of the negative charge is 
neutralized by bound Mg2+ ions in the monomeric structure. In the dimeric structure 
some residues of a symmetry related molecule is making contacts with the aspartates in 
the negative cluster. 
The structural fold of the monomeric structure is very similar to the other 
published SRCR domain structures, such as those of hepsin, M2BP and CD5 
(Hohenester et al., 1999; Rodamilans et al., 2007; Somoza et al., 2003). The SRCR 
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domains of M2BP and MARCO belong to class A SRCR domains and the structures 
differ only in the lengths of loops AB and DE. In the structure of class B SRCR domain 
of CD5 there is an additional disulfide bond that stabilizes the β-strand B in place. The 
SRCR domain of Hepsin has slightly different disulfide bond pattern. The surface 
electrostatic potentials vary dramatically in each of these structures. This is also true for 
a modeled structure of SR-A, in which the negative cluster is slightly smaller and 
closely flanked by a positive cluster. Other proteins sharing parts of the fold include 
toxin II from the scorpion Androctonus australis and antibacterial protein sapecin. 
These structures align well with the α-helix and β-strands D and F of MARCO SRCR 
domain, the region indicated in ligand binding.  
Next, the importance of the positively charged cluster in the MARCO SRCR 
domain for cell adhesion to gelatin-coated surfaces was tested by a set of constructs 
where different combinations of the arginines were mutated. The results indicate that 
the adhesion is achieved co-operatively through several arginines, since none of the 
single mutations affected the adhesion, whereas several of the combinatorial mutants 
lost the adhesion completely. Many of the same mutants also showed low binding of 
AcLDL. In another set of experiments the mutations were directed to the negative 
cluster. Strikingly, double mutations of D447 and D448, as well as a single mutation of 
E511 showed very low adhesion to gelatin, did not bind to AcLDL, and failed to induce 
typical morphological changes to the cells (Pikkarainen et al., 1999). Interestingly, a 
combination of these mutations reversed the affects completely. Since the residues in 
the acidic cluster of MARCO SRCR domain participated in ion binding, the adhesion 
to gelatin-coated surfaces was tested in the presence and absence of divalent ions. 
Indeed, the experiments showed that the presence of Ca2+ was required. Similar results 
were obtained in the presence of Mn2+ but not in the presence of Mg2+. Interestingly, 
the acidic cluster’s triple mutant did not require ions for the adhesion. When cell 
adhesion of the mutants in both groups were tested on poly I coated surfaces, similar 
results were obtained.  
We found earlier that SCARA5 has low affinity for the prototypical scavenger 
receptor ligand AcLDL (Figure 4). Similar results have been reported for human 
MARCO (Elshourbagy et al., 2000), which indicates that small differences between the 
SRCR domain sequences affect the binding to AcLDL. However, arginines do not 
seem to play such a crucial role since only arginines 422 and 466 are different between 
the 74% identical human and mouse sequences. To test which residues are required for 
the binding, we generated chimeric proteins where the mouse SRCR domain was 
replaced by the whole human SRCR domain or parts of it. First, we found that both 
human MARCO and the mouse MARCO chimera with human SRCR domain did 
exhibit some binding of AcLDL. Regardless, when the human SRCR domain sequence 
was changed back to the mouse sequence at the end of the molecule (residues 496-518) 
the same way as was done for SCARA5 earlier (IW and NC mutants), increased 
binding of AcLDL was observed. The binding was even stronger when residues 453-
518 were changed into mouse sequence. In contrast, a chimera with residues 449-473 
from mouse MARCO had no effect on AcLDL binding indicating that the residues 
affecting the binding reside between residues 473-518.  
 
 
 
 
  25 
4.3 SCARA5 EXPRESSION IMPROVES VIABILITY OF MAMMALIAN 
CELLS IN SERUM-FREE CULTURE CONDITIONS AND CAN BE 
USED AS AN ALTERNATIVE TO ANTIBIOTICS FOR SELECTING 
STABLE PROTEIN-PRODUCING CELL LINES (PAPER III) 
Selected HEK-293 EBNA cells expressing the globular subdomains 1-3 (LN3G) of the 
mouse laminin α3 chain showed very low adhesion to cell culture plastic and did not 
survive in the serum-free conditions during protein production. Since the produced 
laminin fragment represents the main adhesive site of laminin-332, we suspected that 
the produced recombinant protein is disrupting the normal cell adhesion by blocking 
the integrin interaction (Miner and Yurchenco, 2004). As opposed to integrin-laminin 
mediated adhesion, studies I and II showed that MARCO mediates strong adhesion to 
surfaces coated with gelatin or poly I, whereas regular HEK-293 or CHO cells showed 
very low affinity to these surfaces. In addition, we had observed that SCARA5 also 
mediates strong adhesion to cell culture plastic and gelatin coated surfaces.  
Therefore, in an attempt to circumvent the adhesion problem, the LN3G 
expressing cells were co-transfected with SCARA5. Indeed, a significantly higher 
adhesion on cell culture plastic was observed on cells expressing SCARA5 and the 
protein production was successful. In fact, SCARA5 positive cells produced up to 
twofold higher levels of recombinant proteins than the parental cells. Furthermore, it 
was evident that SCARA5 positive cells showed increased cell viability in the serum-
free culture conditions further facilitating the protein production. In further tests we 
could show that SCARA5-mediated adhesion was cation-independent and could be 
blocked by poly I treatment. 
Prompted by these results, we sought to explore SCARA5 adhesion for selecting 
stable clones for protein production. For the selection, we chose to use gelatin coated 
surfaces because the most often used cells lines for protein production such as HEK-
293 and CHO cells were unable to adhere to these surfaces. Other tested cell types 
(C3H 10T1/12, NIH 3T3, COS-1, HeLa, and L929) adhered on their own to gelatin 
coated surfaces. To be able to monitor the selection process, we generated a GFP-
IRES-SCARA5 selection construct that produces a single mRNA for both GFP and 
SCARA5. When the number of green cells were quantified by flow cytometry before 
and after the selection procedure, up to 60-fold increase could be detected in the cell 
population left after selection. Similar results could be seen when the cells were left 
adherent and the expression of GFP and SCARA5 was examined by 
immunofluorescence.  
 
4.4 DEFICIENCY OF FIBROBLAST EXPRESSED SCARA5 IN MICE 
CAUSES AUTOIMMUNE DISEASE -LIKE PHENOTYPE (PAPER IV) 
A novel class A scavenger receptor was identified while doing data mining in the NCBI 
public database with MARCO SRCR domain sequence. The sequence was well 
conserved between species and had a very similar domain structure as both MARCO 
and SR-A that had previously been studied in our laboratory. To study if this new 
receptor had similar immune related functions as MARCO and SR-A, we generated 
gene knockout mice, cloned the cDNA, and studied its expression pattern in different 
tissues at both the RNA and protein level by several methods. During the progress of 
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this study, identification of the same protein, termed Tesr or SCARA5, was reported 
(Jiang et al., 2006; Sarraj et al., 2005).  
In our initial screen by Northern blot and RT-PCR analysis, we found SCARA5 
mRNA in almost all the tissues. The broad tissue expression pattern at protein level was 
confirmed by Western blot analysis from different tissue lysates. The Western blot 
analysis indicated that SCARA5 exists in vivo as a trimeric molecule. Each subunit has 
apparent molecular weight of ~90 kDa, which suggests that the protein is heavily 
glycosylated. 
Based on structural similarity to MARCO and SR-A, we expected to find the 
protein in macrophages. However, the initial immunohistochemical stainings of 
different tissues suggested otherwise. Co-localization studies and confocal microscopy 
with markers staining endothelial cells (CD31), macrophages (F4/80, CD11b), and 
different fibroblasts populations (ASMA, vimentin, PDGFRα, FSP) revealed that 
SCARA5 expression is restricted to a subpopulation of fibroblasts. Notably, the 
expression overlapped mostly with vimentin and PDGFRα (Figure 9), which are highly 
expressed in fibroblasts.  
 
 
 
Figure 9. SCARA5 is co-expressed in vimentin and PDGFRα  -positive fibroblasts. 
Immunofluorescence staining and confocal microscopy of esophageal (upper row) and tongue (lower 
row) tissue sections with antibodies recognizing SCARA5 (white), vimentin (red) first panel, ASMA 
(red) second panel, CD 31 (red) third panel, F4/80 (red) fourth panel and CD11b (red) fifth panel. 
PDGFRα expression is seen as green nuclear signal, because the sections were obtained from mice in 
which a nuclear localized H2B-eGFP fusion gene is expressed from the endogenous Pdgfrα locus 
(Hamilton et al., 2003). Rest of the nuclei were stained with DAPI (blue). Indent, 2.7 x additional 
magnification. SCARA5 is co-expressed with vimentin and PDGFRα positive cells but not of those 
expressing ASMA, CD31, F4/80 or CD11b. 
 
Additional expression of SCARA5 was found in the apical side of sertoli cells in 
testis epithelium and the epithelial cells of choroid plexus. Of note, SCARA5 positive 
cells in choroid plexus express PDGFRα (unpublished data) and vimentin expression is 
seen in the basal side of sertoli cells, while PDGFRα expression is located in the 
interstitial cells. Fibroblast expression of SCARA5 was also found in isolated primary 
fibroblasts and several fibroblast cell lines, whereas no expression was seen in 
macrophage cell lines. Furthermore, other sources of immune cells (whole blood, 
Spleen B- and T-cells, lymph node, peritoneal macrophages, dendritic cells, and bone 
marrow) showed no SCARA5 expression, even though they expressed other types of 
class A scavenger receptors. 
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It was previously shown that SCARA5 cells do not bind avidly to prototypic 
scavenger receptor ligand AcLDL (Figure 4) (Chen et al., 2006; Jiang et al., 2006). 
However, similar to MARCO and SR-A, SCARA5 was found to be an endocytic 
receptor binding strongly to E.coli and LPS, the outer cell wall component of Gram-
negative bacteria. 
In order to study the in vivo function of SCARA5, knockout mice were generated 
where the DNA sequence encoding the transmembrane region of the protein was 
deleted. The knockout mice were born with normal Mendelian distribution and showed 
no apparent dysfunctions at young age even though no functional SCARA5 protein 
could be detected. At around 6 months of age several SCARA5 deficient mice were 
found to have lymphocyte infiltrates in several organs. The inflammatory reactions 
were seen most prominently in the lung with severe lymphocyte infiltrates around 
pulmonary arteries, accumulation of Ig-producing plasma cells and macrophages and 
necrotic pseudogranulomatous nodules. Similar symptoms can be seen in several types 
of autoimmune conditions such as Sjögren’s disease, SLE and rheumatoid arthritis. To 
support the notion that the symptoms seen in the SCARA5 deficient mice are of 
autoimmune disease –type, a significant number of the knockout mice were found to 
develop autoantibodies against nuclear proteins.  
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5 DISCUSSION  
In this work we aimed to study the ligand-binding function of mouse MARCO and later 
on the physiological function of another related scavenger receptor SCARA5. Our 
finding of hydrophobic peptides binding to the SRCR domain of MARCO was 
surprising, since most scavenger receptor ligands identified so far such as Gram-
negative and –positive bacteria are polyanionic in nature (Brannstrom et al., 2002; 
Elomaa et al., 1998). On the other hand, it should be noted that MARCO has been 
shown to bind diverse other molecules such as apoptotic cells, UGRP1, myramyl 
dipeptide (MPD) and environmental particles (Bin et al., 2003; Mukhopadhyay et al., 
2011; Palecanda et al., 1999; Wermeling et al., 2007). In contrast to earlier cell-based 
studies where other cell surface molecules may affect the binding, we were able to 
utilize cell-free systems with soluble forms of MARCO to show binding of the major 
cell wall components of Gram-negative and –positive bacteria, LPS and LTA, 
respectively. However, these polyanions had much faster dissociation kinetics than the 
identified peptides or poly I, the commonly used polyanionic ligand-binding inhibitor 
of scavenger receptors. In contrast, there was no specific binding to another polyanionic 
molecule heparin.  
In our database searches with the most enriched peptide sequence 
VRWGSFAAWL, most matches were from the transmembrane sequences of various 
proteins and were disregarded even keeping in mind that such sequences could be 
recognized e. g. on the surface of apoptotic cells. As a potential ligand for MARCO a 
nearly matching sequence GSYAAWL could be identified in another innate immunity 
effector molecule complement component C4. Indeed, we could detect binding to C4b 
and C4d. C4d is a physiological degradation fragment of C4b. These are the forms of 
C4 that act as opsonins once bound to the surface of a bacterium. Interestingly, the 
complement component iC3b, another opsonizing complement factor, was identified as 
a ligand binding to the SRCR domain of SR-AI (Goh et al., 2010). However, the true 
ligand corresponding to the peptide sequence still remains to be identified, since the 
binding of C4b could not be blocked by the peptide. Furthermore, a close examination 
of the C4d structure suggest that only the WL sequence is exposed indicating that the 
identified sequence in C4 is not participating to the binding (van den Elsen et al., 2002).  
Even without identifying the true ligand corresponding to the peptide sequence, 
we wanted further characterize the ligand-binding site in MARCO. Rotary-shadowing 
microscopy showed that sMARCO used for phage-display screening is a rather long 
(~80 nm) rod-like molecule composed of a spacer region, a long collagenous domain 
and the C-terminal SRCR domain making it hard to pinpoint the ligand-binding site 
(Sankala et al., 2002). As for the other MARCO ligands identified earlier, our cell-
studies with MARCO protein devoid of the SRCR domain showed that the isolated 
peptide binds to the SRCR domain. However, there was no binding to a bacteria-
binding MARCO version extending 17 residues to the SRCR domain (Brannstrom et 
al., 2002; Elomaa et al., 1998). As a further confirmation, we could also show binding 
of the peptide to a purified SRCR domain. However, there was a clear difference 
between the number of phages bound to the SRCR domain and sMARCO indicating 
that there is a difference in the binding affinity. Interestingly, similar affinity 
differences were seen when bacteria binding was studied on surfaces coated with 
sMARCO and the SRCR domain (Sankala et al., 2002). Whether the difference is due 
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to avidity or difference in the way proteins are coated to the surface remains to be seen; 
when a single homotrimeric sMARCO with a long collagenous stalk and three SRCR 
domains participating to the binding is coated on a surface it is likely that the SRCR 
domains would still be readily available for binding (Sankala et al., 2002). 
 Further tests showed that the 74% identical human counterpart of the domain 
was also able to bind to the peptide, but there was no binding to a 45 % identical SRCR 
domain of SCARA5. When the SRCR domain sequence of SCARA5 was replaced by 
the mouse SRCR domain sequence or residues 423-481 (IW) and 423-507 (NC), the 
binding was restored indicating that the last 11 residues of the domain are not involved 
in peptide binding. In the crystal structure of the mouse MARCO SRCR domain the IW 
sequence encompasses most of the positively charged β-beta sheet structure (A-E) and 
the α-helix. NC sequence includes even the negatively charged long loop region, but 
lacks the last β-strand F residing in the middle of the β-sheet.  Since SCARA5 binds 
normally very weakly to AcLDL, we tested the binding of AcLDL to these SCARA5 
mutants as well. In contrast to the peptide binding, only the intact form of MARCO 
SRCR was able to bind AcLDL indicating that the negatively charged long loop region 
and/or β-strand F participate in binding. Comparison of the SCARA5 and MARCO 
sequences (GHAEDAGVTCTVP and VHNEDAGVECS, respectively) in the changed 
β-strand reveals only minor changes. However, a careful examination of the mouse 
MARCO SRCR structure revealed that mutation of E516 may alter the conformation of 
R431 and R468, which altogether normally form a structural RXR motif previously 
shown to be important for ligand binding (Brannstrom et al., 2002). As an indication 
how negatively charged molecules bind to this region, there is a sulfate ion coordinated 
to the arginines in the dimeric SRCR structure. An additional SCARA5 mutant was 
made, where the SRCR domain was from SR-AI. Since the ligand-binding region of 
SR-A was previously mapped to the end of the collagenous region (Doi et al., 1993) we 
were surprised to detect avid binding to AcLDL. This was the first evidence showing 
that the SRCR domain of SR-AI has a specific function, since the SR-AII splice variant 
lacking the SRCR domain has been shown to bind to the same ligands with only 
slightly different affinity (Peiser et al., 2000; Peiser et al., 2006). Supporting our 
finding, it was recently reported that the SRCR domain of SR-A is the binding site for 
iC3b (Goh et al., 2010). 
After solving the crystal structure of mouse MARCO SRCR domain, it was 
evident that the domain contains a large positively charged cluster in the β-sheet region 
mentioned above. This large β-sheet region was especially prominent (~26 x 15 Å) in 
the dimeric structure and is likely the binding region for the polyanionic ligands of 
MARCO. For example, similar type of eight-stranded β-pleaded sheet (~30 x 12 Å) 
represents the major peptide-binding groove in MHC molecules (Madden, 1995). More 
importantly, this region contains three linear and two structural RXR motifs implied in 
ligand binding (Brannstrom et al., 2002).  Therefore, a set of arginine mutants was 
generated to further characterize the binding of AcLDL to this region. The binding 
turned out to be co-operative and only multiple mutations affecting both structural 
RXR motifs caused defective binding. However, arginines are not the only residues 
affecting AcLDL binding (E516 above), since the human SRCR domain with most 
arginines still in same places is not able to bind AcLDL (Elomaa et al., 1998).  The 
mutants where the human sequence was changed to the mouse sequence suggest that 
the residues affecting the AcLDL binding lie between residues 474 and 518 and may 
confer major changes in the long loop region of the structure. Unexpectedly, this region 
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of the mouse MARCO SRCR structure turned out to have a net negative charge. 
Indeed, a double mutant of D447 and D448 or a single mutant of E511 within this 
negatively charged region abolished the AcLDL binding. One reason to this could be 
the fact that in the monomeric SRCR structure all of these residues are bound to a Mg2+ 
ion rendering the region more or less neutral. The charge change brought by the bound 
ion could also explain why a triple mutant of D447, D448 and E511 supported AcLDL 
binding. All and all, the residues of both the positively and negatively charged region 
participate in AcLDL binding. Interestingly, these are also the regions expected to 
display most molecular movements and include the peptide sequences in DMBT1 
SRCR domain that participate in ligand binding (Bikker et al., 2013). 
   Apart from ligand binding, we found that the same positive and negative cluster 
mutants of mouse MARCO SRCR domain affect cell adhesion. We used as a 
substratum both gelatin and poly I coated surfaces where normal CHO cells adhere 
poorly. The results indicate that cell adhesion through MARCO SRCR domain is 
mediated by roughly the same regions in the SRCR domain as the ones affecting 
AcLDL binding. Interestingly, the multiple arginine mutant as well as the singular 
negative cluster mutants also abolished the morphological changes with dendritic 
processes typically seen for MARCO transfected cells (Pikkarainen et al., 1999). Yet 
again, this was not the case for the triple mutant of D447, D448 and E511. These 
findings led us to also test if the depletion of divalent cations affects the adhesion of 
MARCO transfected cells to these surfaces. As maybe expected, the negative cluster 
triple mutant was not affected, but normal MARCO mediated adhesion could only be 
restored if Ca2+, Mn2+ or in some degree Mg2+ was present in the cell culture media.  
When we saw lower binding of the phage peptide to the monomeric SRCR 
protein than to the trimeric sMARCO with three SRCR domains in each molecule we 
touched the subject of avidity. Similar effect could also be seen by the need of multiple 
arginines when binding to AcLDL. In fact, these studies were made with cells 
expressing trimeric MARCO molecules, so each single mutation needs to be multiplied 
by three; in essence a single arginine mutation with no effect corresponds to three 
mutated residues in a trimeric molecule whereas there are already nine mutated residues 
in a triple mutant. Keeping this in mind it is quite striking that single mutations such as 
E511 or E516 would have such a dramatic effect on ligand binding. However, when the 
overall structural changes caused by these mutations are examined it can be seen that 
E511 affects the binding of ions and thereby changes the charge of the whole region 
and E516 destabilizes the orientation of two arginine residues and therefore actually 
counts as a triple mutant. Another feature affecting the avidity could come from the 
dimeric structure that is essentially a β-strand-swapped form of two monomers. For 
example in the case of diphteria toxin domain-swapping is induced by ligand binding 
(Louie et al., 1997). Thus, it is easy to envision that the SRCR domains (diameter 
~3nm) from separate MARCO molecules swap domains in order to create oligomerized 
forms of MARCO with multiple binding sites to support the binding of whole bacteria 
(diameter 0.2-2.0 µm) or large macromolecules such as AcLDL (diameter ~25 nm) 
(Coresh et al., 1993). To support this notion, sMARCO molecules were often detected 
as oligomers in the rotary-shadowing images (Sankala et al., 2002). It is interesting to 
note here the MARCO mutant extending 17 residues to the SRCR domain reported to 
bind bacteria still has left all the residues involved in the domain-swapping in the 
dimeric structure and is therefore still able to form oligomers (Brannstrom et al., 2002). 
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As discussed earlier, MARCO supported cell adhesion to gelatin and poly I 
coated surfaces. Furthermore, the adhesion was found to require residues involved in 
the ion binding within the negative cluster of the SRCR domain structure and the 
presence of Ca2+, Mn2+ or in some extent Mg2+. When compared, all the residues 
involved in the ion binding are conserved between MARCO, SR-A and SCARA5, 
indicating that also SR-A and SCARA5 would function the same. Indeed, similar to 
MARCO both receptors show strong adhesion to tissue culture plastic but the adhesion 
was shown to be cation-independent (Fraser et al., 1993). Here it is important to note 
that the adhesion experiments with MARCO were made in a different manner; 
MARCO cells were incubated with a chelating agent in the suspension prior to plating 
to a gelatin coated surface while cell culture plastic adherent SR-A and SCARA5 cells 
were used. In the latter case, the ion supporting cell adhesion might be inaccessible to 
the chelating agent or there is a specific ion-dependent contact between MARCO and 
gelatin, which as a ligand differs dramatically from tissue culture plastic. Interestingly, 
SR-A mediated adhesion to cell culture plastic seems to block the bacteria/AcLDL -
binding capacity of the receptor while cells plated on bacteriological plastic show avid 
binding (Peiser et al., 2000). Regardless of the adhesion mechanism, we found that 
SCARA5 supported adhesion increased the cell viability of cells used for protein 
production in serum-free culture conditions. This is an important feature, which can 
reduce protein production costs dramatically since the same cells can be harvested 
several times. In combination with this we could also see an increase in the yield of the 
produced recombinant protein LN3G. In our hands, LN3G-producing cells showed 
extremely low cell adhesion making it impossible to work with the cells. It can 
therefore be postulated that SCARA5 expression can be used to rescue the expression 
of other proteins causing similar type of adhesion problems as LN3G. We also 
exploited the SCARA5 mediated adhesion for clonal selection of stable protein-
producing mammalian cell lines as an alternative to biohazardous and relatively 
expensive antibiotics.  Reducing the costs is one thing, but it is also important to reduce 
the use of antibiotics from the global health perspective where multiresistant bacteria 
causing severe infections are a more and more common trade (Levy and Marshall, 
2004). The method is also very simple and does not rely on specialized equipment 
needed in many traditionally used techniques (DeMaria et al., 2007; Sleiman et al., 
2008). 
Our results on SCARA5 provide new knowledge about fibroblasts. These cells 
have traditionally been considered as relatively inert cell population of connective 
tissue responsible for giving support to surrounding tissues by producing extracellular 
matrix (ECM) (Sorrell and Caplan, 2009). Thus finding a bacteria- and LPS-
internalizing scavenger receptor SCARA5 on fibroblasts instead of macrophages, and 
an autoimmune disease like phenotype in knockout mice is intriguing as it suggests 
hitherto unknown properties for fibroblasts in tissue homeostasis. This data also 
contrasts another in situ hybridization-based study, where SCARA5 was localized to 
epithelial cells, that we could only confirm for the epithelial cells of choroid plexus and 
testis seminiferous tubules (Jiang et al., 2006; Sarraj et al., 2005). 
In line with our present data, some other recent studies have described fibroblasts 
as a diverse cell population mediating important stromal cell – immune cell interactions 
which regulate the switch from acute inflammation to adaptive immunity and tissue 
repair (Buckley et al., 2001; Roozendaal and Mebius, 2011). Indeed, fibroblasts have 
been shown to express various chemokines and CD40, which regulates the infiltrated 
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hematopoetic cells via CD40 ligand (L) interaction (Brouty-Boye et al., 2000). Even a 
circulating antigen-presenting fibroblast population, fibrocytes, has been identified 
(Bucala et al., 1994; Chesney et al., 1997). Our results indicated that SCARA5 is only 
expressed by a subpopulation of fibroblasts (PDGFRα and vimentin positive, mostly 
FSP negative) positioned mostly in places where they can participate in clearance 
function e. g. submucosal fibroblasts in the small intestine and fibroblasts surrounding 
the pulmonary arteries. Interestingly most of these locations e.g urinary bladder are also 
going through huge elastic movements that may require a certain type of expression 
profile on the fibroblasts.  
Disturbances in the fibroblast function have been suggested to lead to chronic 
inflammation and ectopic accumulation of lymphoid cells in structures called tertiary 
lymphoid organs (Buckley et al., 2001; Drayton et al., 2006; Roozendaal and Mebius, 
2011). Such findings are often associated with autoimmune diseases such as 
Rheumatoid arthritis, Sjögrens’s syndrome and multiple sclerosis and resemble closely 
the lymphoid cell infiltrates seen in multiple organs of SCARA5 deficient mice 
(Drayton et al., 2006). The additional finding of antinuclear antibodies in the mice 
further suggests that the lack of SCARA5 in the fibroblasts leads to autoimmune 
disease and dysfunctional regulation of adaptive immunity. It is thought that 
autoantibodies arise from dysregulation of T- and B-cell differentiation, that are both 
dependent on the cytokine environment and interaction with antigen presenting 
dendritic cells (Buckley et al., 2001; Drayton et al., 2006).  Interestingly, it was shown 
that thymic fibroblasts play an important role in T-cell development and a PDGFRα -
positive fibroblast population, which we could also identify as SCARA5 positive, is 
involved (Gray et al., 2007; Suniara et al., 2000). Furthermore, both SR-A and 
MARCO have been associated with autoimmune disease SLE. The patients develop 
autoantibodies against the receptors that lead to impaired removal of apoptotic cells 
(Chen et al., 2011; Rogers et al., 2009; Wermeling et al., 2007). How these receptors 
function in regulating autoimmunity is not fully understood but they may well share the 
mechanisms with SCARA5. Some studies how the processes works in case of MARCO 
and SR-A have been made. For example, MARCO positive cells have been shown to 
interact with B-cells (Karlsson et al., 2003). SR-A was shown to shape antigen 
presentation by mediating antigen transfer between B-cells and macrophages (Harvey 
et al., 2008; Raycroft et al., 2012). SR-A and T-cell involvement has also been studied 
in hepatitis patients and EAE multiple sclerosis model (Levy-Barazany and Frenkel, 
2012; Zuo et al., 2013). 
Another interesting aspect of fibroblast function and SCARA5’s role in it is 
cancer-associated fibroblasts (CAF). CAFs are important regulators of the tumor 
progression, growth, and spreading (Kalluri and Zeisberg, 2006). As discussed earlier, 
fibroblasts are a heterogenous population and in tumor environment fibroblasts with 
varying degrees of PDGFRα, ASMA and FSP expression are found (Anderberg and 
Pietras, 2009; Kalluri and Zeisberg, 2006). The ASMA and FSP expressing fibroblasts 
are regarded as activated fibroblasts gradually losing the expression of PDGFRα 
(Anderberg et al., 2009; Kalluri and Zeisberg, 2006). Do SCARA5 positive fibroblasts 
go through this process since they are positive for PDGFRα but negative for FSP? 
Interestingly, SCARA5 expression was downregulated in several human hepatocellular 
carcinoma cell lines and tumor samples. It was also shown to limit the tumor growth 
and metastasis in mice (Huang et al., 2010; Yan et al., 2012).  
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6 CONCLUDING REMARKS 
This study clearly demonstrates that scavenger receptors MARCO and SCARA5 play a 
role in host defense function - whether against endogenous proteins or microorganisms. 
Importantly, these two receptors are located on very different cell types, macrophages 
and fibroblasts, respectively. However, even after we were able to identify the SRCR 
domain as the main functional domain of MARCO and analyze the structure in detail, it 
is still not totally clear how the binding of large ligands such as bacteria or modified 
LDL is truly achieved. Everything suggests that multiple copies of the domain are 
required. Indeed there are three SRCR domains in each naturally occurring trimeric 
form of cell surface expressed MARCO, is this really enough? The dimensions still 
suggest otherwise and maybe oligomerization is needed as was suggested by the 
finding of the dimeric structure and oligomers seen in the rotary shadowing images 
(Sankala et al., 2002). Keeping this in mind, it would be interesting to solve the 
structure of a trimeric scavenger receptor molecule with a bound ligand. Some trials 
were naturally made, but the soluble form of MARCO is quite large molecule to work 
with and poses problems not only in the production, but also in the solubility and 
heterogeneity of the protein – problems not very desirable for any crystallization trials. 
There are things to be done to circumvent all these problems, but maybe the most 
natural choice is to look at the structure with the help of single particle microscopy and 
electron tomography. 
We have also seen that MARCO deficient mice are more susceptible to various 
infections and therefore it raises a question whether these proteins could be used as 
therapeutic agents. This would be a quite attractive alternative to the use of antibiotics.  
These proteins sequences have been evolutionally tested for thousands of years and 
therefore bacteria are unlikely able to generate resistance against these proteins. It 
seems also natural to use our own innate immune system to boost the immune 
reactions, since these molecules are unlikely to have as dramatic toxic effects as some 
pharmaceuticals. Here, however it is good to keep in mind that both MARCO and 
SCARA5 seem to be involved in the development of autoimmune reactions and the 
question is whether a treatment with soluble receptors would lead to the development 
of an autoimmune disease or could it actually be the solution resolving one. Regardless, 
it is clear that more studies need to be made in order to understand the mechanism 
behind their function. 
When it comes to SCARA5 and the knockout mice generated in this study, I feel 
that we have basically just now generated the tools to study its function and function of 
fibroblasts, the most common cell type of the interstitial connective tissue. The mice 
studied in this study were unchallenged, so what happens to the mice under different 
autoimmune disease models? What happens if they are infected with different bacteria? 
What is the role of these fibroblasts at different sites? Are the mice more prone to 
develop tumors? What is the role of SCARA5 in the testis – why do the male mice 
become infertile? I am looking forward to finding answers to these and countless other 
questions that are bound to arise. 
  34 
7 ACKNOWLEDGEMENTS 
First and foremost I want to thank my supervisor Karl Tryggvason. I was fascinated 
by his scientific accomplishments and vision and found myself at his office all those 
years ago asking for the opportunity to start working on my PhD. Who knows what he 
saw in me and my rather juvenile ideas back then, but I am truly grateful for the 
opportunity I was given. I cannot imagine any other place with as many resources; the 
possibility to use all these techniques and to work on such a versatile project was a 
dream come true for me. 
 
I thank all the collaborators and co-authors. I am also grateful for the funding provided 
by grants from Swedish Research Council, the Foundation for Strategic Research 
(Sweden), Canadian Institutes of Health Research, Sigrid Jusélius Foundation, Knut 
and Alice Wallenberg Foundation, Swedish Cancer Foundation, Söderberg´s 
Foundation, Hedlund´s Foundation, Robert Lundberg´s and the Novo Nordisk 
Foundation. 
  
I want to thank my co-supervisor Ari Tuuttila for all the help in the beginning of this 
journey and all the fun we had while you were still in Stockholm. Timo Pikkarainen 
deserves enormous thanks for being there throughout all these years. One cannot hope 
for any better colleague to work with. You were always there to listen, give advice and 
discuss all that comes with science and otherwise – I think you were the one who made 
me start running! 
   
I owe Berit my deepest gratitude for all the help I have received. I can honestly say that 
I don’t know what I did to deserve to have you around.  
 
I am grateful to all the past (There were so many…here are some: Pekka, Annika, 
Ulla, Anneli, Ljubica, Tiina, Marko, Ari, Timo P, Timo J, Anna, Mataleena, Sam, 
Eyrún, Stefania, Olga, Arindam, Xiangjun, Lwaki, Mark, Elisabeth, Katja, 
Massa, Rickard, Labassistant girls, Yi, Yunying, Li, Meihua, Zhijie, Laleh, Linda, 
Kerstin, Dadi, Zhongjun, Mao) and current members (Jonas, Ásmundur, Jaakko, 
Olle, Berit, Bing, Anne-May, Patricia, Jing, Sergey, Kan, Anna, Ann-Sofie, Lotta) 
of Matrix biology for all the good times we have shared in the lab and outside. 
 
I specially want to thank Ási for the trips and parties we shared; I especially cherish the 
memories of Syöte Challenge in Finland and the road trip in Island. Jaakko was also 
part of our team in Syöte Challenge, but we were also “brothers” in Egypt, spent 
numerous Midsummers in Finland, many New Years celebrations in Norway and you 
have been a worthy adversary in all the games we have played. Sergey for all the poker 
nights and for being the most reliable bowling buddy. Mark for pushing me to run and 
the reward: burgers and beer after each Hässelby loppet race. Kan and Bing for all the 
shared lunches. Zhijie for all the trips (Hållö, conferences) and parties; hope you don’t 
have too many silly pictures of me! Anne-May for all the nice hikes and chats we have 
had! And thanks a lot for keeping the coffee supply in check. Elisabeth and Mataleena 
for being the most fun company; I will never forget our first dance at Grappa! For all 
the skiing trips in Sweden and in the Alps with at least Stefania, Zhijie, Li, Eyrún, 
  35 
Olga, Marko, Sam, Massa and Linda. Timo J for all the inspiring discussions. Massa 
for the friendship, our “healthy” competition, and of course the nice trips to Japan and 
elsewhere. Tiina and Marko for being the cool Finns in the lab when I arrived and all 
the fun we had!  
 
Our hiking crew Tiina, Marko, Paula, Mirta, Massa and Li. Don’t you think it’s time 
for a next destination? 
 
I thank all the present and former people in the Vascular Biology unit – is it group of 
four or five now?  Anyway, it has been a privilege to have you all around! We have 
shared some great times together at various occasions but maybe the most memorable 
ones have been the Christmas parties – maybe I can take some credit for that ;) 
 
I thank specifically the people who made the dinner parties in the kitchen happen 
(Pernilla, Erika, Annelie, Jen, Lars M, Sebastian, Colin, Lars J., Carolina, Jill, 
Joel, Elisabeth, Daniel, Sara, Linda, Maya and others who joined). I want to also 
thank our BBBBB (Blood brain barrier boys and babes) running team Maarja, Lars J., 
Tom, Olle, Arnold and Johanna. Of course we had most fun competing against other 
teams from the lab! Maarja for being the best training companion at the gym, yoga and 
running track. Ingrid, Barbara, Jen, Erika and Joel for joining the running practice 
sessions and making them more fun. A special thanks to our coach Jason! I thank 
Eliane, Annika, Philip, Hanna, Nik and Konstantin for all the climbing sessions. 
Colin for hosting all the game nights. Radiosa for all the movie nights, night skating, 
parties, trips to Tallin and Milan, being a confocal guru, you name it! Jen who has 
taken over the role of being my movie buddy. Barbara for showing me places to see 
and things to do in Stockholm. Sara for listening and helping me with the paperwork 
and preparations for the defence. Karin S. for being the coolest person to share lots of 
fun in Stockholm and elsewhere. Maya for being the long lasting friend, travel 
companion and training buddy. 
 
I am grateful for the structure guys Bernie, Dominik, Jason, Doreen, Robert, 
Katharina, Maria, Rajesh and Ömer for welcoming me to join for countless after 
work beers. Special thanks to Dominik for all the climbing sessions, Bernie for all the 
scientific discussions and Oktoberfest at your hometown. Jason for being the kindred 
spirit in many ways and all the late night discussions or shall I say arguments – I sure 
miss them! Rajesh for many fun bowling evenings – it’s not the same without you!   
 
I also want to thank people from the inflammation group. Jonatan, Michael, Erik, and 
Sabrina for having us over at The House for so many nights. Bruno, Franziska, 
Ulrika, Angela and Chris for sharing the fun most of those evenings. 
 
I thank other people at work: Viktoria, Jenny, Johanna, Essam, Frank, Andreas, 
Erica, Chad, Torbjörn, Alessandra, David, Pia, Jens, Sarah, Svante, Gunvor, 
Susan and Ulla. One way or another you have made my life better and MBB a nice 
place to work.    
 
I thank Wednesday football guys Edvard, Joel, Massa, Bernie, Jaakko, David, 
Bruno, Colin, Ási for all the sweat and glory! I had no idea how to play in the 
  36 
beginning so Massa deserves a special thanks for making me start and giving me a 
reason to at least sometimes pretend to care about football and if Barca wins.  
 
 
 
I thank my other friends Anna K. and Riikka for all the good times we have shared 
during the studies and after. Maria and Anna K for being there when I moved to 
Stockholm. Wouter, Anna M. and Nazariy for sharing countless fun nights, trips and 
games with the rest of the gang. Hanna, Åsa and Lisa for all the dinners and fun game 
evenings. Special thanks to Åsa for introducing me to sailing. The members of 
Crazylegs especially Ulf, Sarah, Thomas, Kristin, Anneli, Stina, Marie, Anna L, 
Jonas, Erik, Therese and Pauline for all the fun on the dance floor and during 
practise.  
 
Kiitos äidille ja isälle kaikesta! Kiitos Sirpalle, Riitalle ja Markolle sekä muulle 
perheelle yhteisitä vuosista. Olen saanut kaikki valmiudet ja rohkeuden tehdä sen mitä 
elämässäni haluan kaikkien niiden kokemuksien ja elämänviisauksien kautta jotka olen 
teiltä oppinut. 
 
Kiitos kaikesta tuesta ja turvasta Saaralle ja Timolle sekä Harrille ja Mialle 
perheineen täällä Tukholmassa. Olette kuin toinen perhe! 
 
  
 
 
 
 
 
 
 
  37 
8 REFERENCES 
Anderberg, C., Li, H., Fredriksson, L., Andrae, J., Betsholtz, C., Li, X., Eriksson, U., 
and Pietras, K. (2009). Paracrine signaling by platelet-derived growth factor-CC 
promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer 
Res 69, 369-378. 
Anderberg, C., and Pietras, K. (2009). On the origin of cancer-associated fibroblasts. 
Cell Cycle 8, 1461-1462. 
Antoni, G., Oudot-Mellakh, T., Dimitromanolakis, A., Germain, M., Cohen, W., Wells, 
P., Lathrop, M., Gagnon, F., Morange, P.E., and Tregouet, D.A. (2011). 
Combined analysis of three genome-wide association studies on vWF and FVIII 
plasma levels. BMC Med Genet 12, 102. 
Areschoug, T., and Gordon, S. (2008). Pattern recognition receptors and their role in 
innate immunity: focus on microbial protein ligands. Contrib Microbiol 15, 45-
60. 
Arredouani, M., Yang, Z., Ning, Y., Qin, G., Soininen, R., Tryggvason, K., and 
Kobzik, L. (2004). The scavenger receptor MARCO is required for lung defense 
against pneumococcal pneumonia and inhaled particles. J Exp Med 200, 267-272. 
Arredouani, M.S., Franco, F., Imrich, A., Fedulov, A., Lu, X., Perkins, D., Soininen, 
R., Tryggvason, K., Shapiro, S.D., and Kobzik, L. (2007). Scavenger Receptors 
SR-AI/II and MARCO limit pulmonary dendritic cell migration and allergic 
airway inflammation. J Immunol 178, 5912-5920. 
Arredouani, M.S., Palecanda, A., Koziel, H., Huang, Y.C., Imrich, A., Sulahian, T.H., 
Ning, Y.Y., Yang, Z., Pikkarainen, T., Sankala, M., et al. (2005). MARCO is the 
major binding receptor for unopsonized particles and bacteria on human alveolar 
macrophages. J Immunol 175, 6058-6064. 
Arredouani, M.S., Yang, Z., Imrich, A., Ning, Y., Qin, G., and Kobzik, L. (2006). The 
macrophage scavenger receptor SR-AI/II and lung defense against pneumococci 
and particles. Am J Respir Cell Mol Biol 35, 474-478. 
Babaev, V.R., Gleaves, L.A., Carter, K.J., Suzuki, H., Kodama, T., Fazio, S., and 
Linton, M.F. (2000). Reduced atherosclerotic lesions in mice deficient for total or 
macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb 
Vasc Biol 20, 2593-2599. 
Bardoel, B.W., and Strijp, J.A. (2011). Molecular battle between host and bacterium: 
recognition in innate immunity. J Mol Recognit 24, 1077-1086. 
Barrett, C.P., Hall, B.A., and Noble, M.E. (2004). Dynamite: a simple way to gain 
insight into protein motions. Acta Crystallogr D Biol Crystallogr 60, 2280-2287. 
Bikker, F.J., Cukkemane, N., Nazmi, K., and Veerman, E.C. (2013). Identification of 
the hydroxyapatite-binding domain of salivary agglutinin. Eur J Oral Sci 121, 7-
12. 
Bikker, F.J., Ligtenberg, A.J., End, C., Renner, M., Blaich, S., Lyer, S., Wittig, R., van't 
Hof, W., Veerman, E.C., Nazmi, K., et al. (2004). Bacteria binding by 
DMBT1/SAG/gp-340 is confined to the VEVLXXXXW motif in its scavenger 
receptor cysteine-rich domains. J Biol Chem 279, 47699-47703. 
Bikker, F.J., Ligtenberg, A.J., Nazmi, K., Veerman, E.C., van't Hof, W., Bolscher, J.G., 
Poustka, A., Nieuw Amerongen, A.V., and Mollenhauer, J. (2002). Identification 
of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), 
a member of the scavenger receptor cysteine-rich superfamily. J Biol Chem 277, 
32109-32115. 
Bin, L.H., Nielson, L.D., Liu, X., Mason, R.J., and Shu, H.B. (2003). Identification of 
uteroglobin-related protein 1 and macrophage scavenger receptor with 
  38 
collagenous structure as a lung-specific ligand-receptor pair. J Immunol 171, 
924-930. 
Bock, A.J., Nymoen, D.A., Brenne, K., Kaern, J., and Davidson, B. (2012). SCARA3 
mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma 
effusions. Hum Pathol 43, 669-674. 
Brannstrom, A., Sankala, M., Tryggvason, K., and Pikkarainen, T. (2002). Arginine 
residues in domain V have a central role for bacteria-binding activity of 
macrophage scavenger receptor MARCO. Biochem Biophys Res Commun 290, 
1462-1469. 
Brogden, K.A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in 
bacteria? Nat Rev Microbiol 3, 238-250. 
Brouty-Boye, D., Pottin-Clemenceau, C., Doucet, C., Jasmin, C., and Azzarone, B. 
(2000). Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 
30, 914-919. 
Brown, M.S., and Goldstein, J.L. (1983). Lipoprotein metabolism in the macrophage: 
implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52, 
223-261. 
Bucala, R., Spiegel, L.A., Chesney, J., Hogan, M., and Cerami, A. (1994). Circulating 
fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol 
Med 1, 71-81. 
Buckley, C.D., Pilling, D., Lord, J.M., Akbar, A.N., Scheel-Toellner, D., and Salmon, 
M. (2001). Fibroblasts regulate the switch from acute resolving to chronic 
persistent inflammation. Trends Immunol 22, 199-204. 
Chen, X.W., Shen, Y., Sun, C.Y., Wu, F.X., Chen, Y., and Yang, C.D. (2011). Anti-
class a scavenger receptor autoantibodies from systemic lupus erythematosus 
patients impair phagocytic clearance of apoptotic cells by macrophages in vitro. 
Arthritis Res Ther 13, R9. 
Chen, Y., Sankala, M., Ojala, J.R., Sun, Y., Tuuttila, A., Isenman, D.E., Tryggvason, 
K., and Pikkarainen, T. (2006). A phage display screen and binding studies with 
acetylated low density lipoprotein provide evidence for the importance of the 
scavenger receptor cysteine-rich (SRCR) domain in the ligand-binding function 
of MARCO. J Biol Chem 281, 12767-12775. 
Chen, Y., Wermeling, F., Sundqvist, J., Jonsson, A.B., Tryggvason, K., Pikkarainen, 
T., and Karlsson, M.C. (2010). A regulatory role for macrophage class A 
scavenger receptors in TLR4-mediated LPS responses. Eur J Immunol 40, 1451-
1460. 
Chesney, J., Bacher, M., Bender, A., and Bucala, R. (1997). The peripheral blood 
fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in 
situ. Proc Natl Acad Sci U S A 94, 6307-6312. 
Coombs, P.J., Graham, S.A., Drickamer, K., and Taylor, M.E. (2005). Selective 
binding of the scavenger receptor C-type lectin to Lewisx trisaccharide and 
related glycan ligands. J Biol Chem 280, 22993-22999. 
Coresh, J., Kwiterovich, P.O., Jr., Smith, H.H., and Bachorik, P.S. (1993). Association 
of plasma triglyceride concentration and LDL particle diameter, density, and 
chemical composition with premature coronary artery disease in men and 
women. J Lipid Res 34, 1687-1697. 
Dahl, M., Bauer, A.K., Arredouani, M., Soininen, R., Tryggvason, K., Kleeberger, 
S.R., and Kobzik, L. (2007). Protection against inhaled oxidants through 
scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. J 
Clin Invest 117, 757-764. 
  39 
DeMaria, C.T., Cairns, V., Schwarz, C., Zhang, J., Guerin, M., Zuena, E., Estes, S., and 
Karey, K.P. (2007). Accelerated clone selection for recombinant CHO cells using 
a FACS-based high-throughput screen. Biotechnol Prog 23, 465-472. 
DeWitte-Orr, S.J., Collins, S.E., Bauer, C.M., Bowdish, D.M., and Mossman, K.L. 
(2010). An accessory to the 'Trinity': SR-As are essential pathogen sensors of 
extracellular dsRNA, mediating entry and leading to subsequent type I IFN 
responses. PLoS Pathog 6, e1000829. 
Doi, T., Higashino, K., Kurihara, Y., Wada, Y., Miyazaki, T., Nakamura, H., Uesugi, 
S., Imanishi, T., Kawabe, Y., Itakura, H., et al. (1993). Charged collagen 
structure mediates the recognition of negatively charged macromolecules by 
macrophage scavenger receptors. J Biol Chem 268, 2126-2133. 
Doria, A., Zen, M., Bettio, S., Gatto, M., Bassi, N., Nalotto, L., Ghirardello, A., 
Iaccarino, L., and Punzi, L. (2012). Autoinflammation and autoimmunity: 
bridging the divide. Autoimmun Rev 12, 22-30. 
Doyle, S.E., O'Connell, R.M., Miranda, G.A., Vaidya, S.A., Chow, E.K., Liu, P.T., 
Suzuki, S., Suzuki, N., Modlin, R.L., Yeh, W.C., et al. (2004). Toll-like receptors 
induce a phagocytic gene program through p38. J Exp Med 199, 81-90. 
Drayton, D.L., Liao, S., Mounzer, R.H., and Ruddle, N.H. (2006). Lymphoid organ 
development: from ontogeny to neogenesis. Nat Immunol 7, 344-353. 
East, L., and Isacke, C.M. (2002). The mannose receptor family. Biochim Biophys 
Acta 1572, 364-386. 
Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A., 
Thesleff, I., Kraal, G., and Tryggvason, K. (1995). Cloning of a novel bacteria-
binding receptor structurally related to scavenger receptors and expressed in a 
subset of macrophages. Cell 80, 603-609. 
Elomaa, O., Sankala, M., Pikkarainen, T., Bergmann, U., Tuuttila, A., Raatikainen-
Ahokas, A., Sariola, H., and Tryggvason, K. (1998). Structure of the human 
macrophage MARCO receptor and characterization of its bacteria-binding 
region. J Biol Chem 273, 4530-4538. 
Elshourbagy, N.A., Li, X., Terrett, J., Vanhorn, S., Gross, M.S., Adamou, J.E., 
Anderson, K.M., Webb, C.L., and Lysko, P.G. (2000). Molecular 
characterization of a human scavenger receptor, human MARCO. Eur J Biochem 
267, 919-926. 
Ezzat, K., Helmfors, H., Tudoran, O., Juks, C., Lindberg, S., Padari, K., El-Andaloussi, 
S., Pooga, M., and Langel, U. (2012). Scavenger receptor-mediated uptake of 
cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J 26, 
1172-1180. 
Feinberg, H., Taylor, M.E., and Weis, W.I. (2007). Scavenger receptor C-type lectin 
binds to the leukocyte cell surface glycan Lewis(x) by a novel mechanism. J Biol 
Chem 282, 17250-17258. 
Fraser, I., Hughes, D., and Gordon, S. (1993). Divalent cation-independent macrophage 
adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature 
364, 343-346. 
Freeman, M., Ashkenas, J., Rees, D.J., Kingsley, D.M., Copeland, N.G., Jenkins, N.A., 
and Krieger, M. (1990). An ancient, highly conserved family of cysteine-rich 
protein domains revealed by cloning type I and type II murine macrophage 
scavenger receptors. Proc Natl Acad Sci U S A 87, 8810-8814. 
Fritz, J.H., Ferrero, R.L., Philpott, D.J., and Girardin, S.E. (2006). Nod-like proteins in 
immunity, inflammation and disease. Nat Immunol 7, 1250-1257. 
Gao, J., Liu, D.P., Huang, Y., Dong, W.J., Wu, M., Feng, D.X., and Liang, C.C. 
(2003). Excessive expression of the scavenger receptor class A type I can 
  40 
significantly affect the serum lipids. Sheng Wu Hua Xue Yu Sheng Wu Wu Li 
Xue Bao (Shanghai) 35, 117-121. 
Garza-Garcia, A., Esposito, D., Rieping, W., Harris, R., Briggs, C., Brown, M.H., and 
Driscoll, P.C. (2008). Three-dimensional solution structure and conformational 
plasticity of the N-terminal scavenger receptor cysteine-rich domain of human 
CD5. J Mol Biol 378, 129-144. 
Ghosh, S., Gregory, D., Smith, A., and Kobzik, L. (2011). MARCO regulates early 
inflammatory responses against influenza: a useful macrophage function with 
adverse outcome. Am J Respir Cell Mol Biol 45, 1036-1044. 
Goh, J.W., Tan, Y.S., Dodds, A.W., Reid, K.B., and Lu, J. (2010). The class A 
macrophage scavenger receptor type I (SR-AI) recognizes complement iC3b and 
mediates NF-kappaB activation. Protein Cell 1, 174-187. 
Gomes, I.N., Palma, L.C., Campos, G.O., Lima, J.G., TF, D.E.A., JP, D.E.M., Ferreira, 
C.A., Santos, R.R., Buck, G.A., Manque, P.A., et al. (2009). The scavenger 
receptor MARCO is involved in Leishmania major infection by CBA/J 
macrophages. Parasite Immunol 31, 188-198. 
Gordon, S. (2002). Pattern recognition receptors: doubling up for the innate immune 
response. Cell 111, 927-930. 
Gough, P.J., Greaves, D.R., and Gordon, S. (1998). A naturally occurring isoform of 
the human macrophage scavenger receptor (SR-A) gene generated by alternative 
splicing blocks modified LDL uptake. J Lipid Res 39, 531-543. 
Graham, S.A., Antonopoulos, A., Hitchen, P.G., Haslam, S.M., Dell, A., Drickamer, 
K., and Taylor, M.E. (2011). Identification of neutrophil granule glycoproteins as 
Lewis(x)-containing ligands cleared by the scavenger receptor C-type lectin. J 
Biol Chem 286, 24336-24349. 
Gray, D.H., Tull, D., Ueno, T., Seach, N., Classon, B.J., Chidgey, A., McConville, 
M.J., and Boyd, R.L. (2007). A unique thymic fibroblast population revealed by 
the monoclonal antibody MTS-15. J Immunol 178, 4956-4965. 
Greenberg, J.W., Fischer, W., and Joiner, K.A. (1996). Influence of lipoteichoic acid 
structure on recognition by the macrophage scavenger receptor. Infect Immun 64, 
3318-3325. 
Hamilton, T.G., Klinghoffer, R.A., Corrin, P.D., and Soriano, P. (2003). Evolutionary 
divergence of platelet-derived growth factor alpha receptor signaling 
mechanisms. Mol Cell Biol 23, 4013-4025. 
Hampton, R.Y., Golenbock, D.T., Penman, M., Krieger, M., and Raetz, C.R. (1991). 
Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 
352, 342-344. 
Han, H.J., Tokino, T., and Nakamura, Y. (1998). CSR, a scavenger receptor-like 
protein with a protective role against cellular damage causedby UV irradiation 
and oxidative stress. Hum Mol Genet 7, 1039-1046. 
Hansen, S., and Holmskov, U. (1998). Structural aspects of collectins and receptors for 
collectins. Immunobiology 199, 165-189. 
Harvey, B.P., Quan, T.E., Rudenga, B.J., Roman, R.M., Craft, J., and Mamula, M.J. 
(2008). Editing antigen presentation: antigen transfer between human B 
lymphocytes and macrophages mediated by class A scavenger receptors. J 
Immunol 181, 4043-4051. 
Hoffmann, J.A., Kafatos, F.C., Janeway, C.A., and Ezekowitz, R.A. (1999). 
Phylogenetic perspectives in innate immunity. Science 284, 1313-1318. 
Hohenester, E., Sasaki, T., and Timpl, R. (1999). Crystal structure of a scavenger 
receptor cysteine-rich domain sheds light on an ancient superfamily. Nat Struct 
Biol 6, 228-232. 
  41 
Hoppe, H.J., and Reid, K.B. (1994). Collectins--soluble proteins containing 
collagenous regions and lectin domains--and their roles in innate immunity. 
Protein Sci 3, 1143-1158. 
Horiuchi, S., Unno, Y., Usui, H., Shikata, K., Takaki, K., Koito, W., Sakamoto, Y., 
Nagai, R., Makino, K., Sasao, A., et al. (2005). Pathological roles of advanced 
glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 1043, 671-
675. 
Huang, J., Zheng, D.L., Qin, F.S., Cheng, N., Chen, H., Wan, B.B., Wang, Y.P., Xiao, 
H.S., and Han, Z.G. (2010). Genetic and epigenetic silencing of SCARA5 may 
contribute to human hepatocellular carcinoma by activating FAK signaling. J 
Clin Invest 120, 223-241. 
Iida, M., Matsumoto, K., Tomita, H., Nakajima, T., Akasawa, A., Ohtani, N.Y., 
Yoshida, N.L., Matsui, K., Nakada, A., Sugita, Y., et al. (2001). Selective down-
regulation of high-affinity IgE receptor (FcepsilonRI) alpha-chain messenger 
RNA among transcriptome in cord blood-derived versus adult peripheral blood-
derived cultured human mast cells. Blood 97, 1016-1022. 
Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recognition. Annu Rev 
Immunol 20, 197-216. 
Janeway, C.A., Travers, P., Walport, M., and Sclomchik, M.J. (2001). Immunobiology: 
the immune system in health and disease, 5 edn (NY, Garland publishing). 
Jang, S., Ohtani, K., Fukuoh, A., Yoshizaki, T., Fukuda, M., Motomura, W., Mori, K., 
Fukuzawa, J., Kitamoto, N., Yoshida, I., et al. (2009). Scavenger receptor 
collectin placenta 1 (CL-P1) predominantly mediates zymosan phagocytosis by 
human vascular endothelial cells. J Biol Chem 284, 3956-3965. 
Jiang, Y., Oliver, P., Davies, K.E., and Platt, N. (2006). Identification and 
characterization of murine SCARA5, a novel class A scavenger receptor that is 
expressed by populations of epithelial cells. J Biol Chem 281, 11834-11845. 
Jozefowski, S., Sulahian, T.H., Arredouani, M., and Kobzik, L. (2006). Role of 
scavenger receptor MARCO in macrophage responses to CpG 
oligodeoxynucleotides. J Leukoc Biol 80, 870-879. 
Kalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401. 
Kamradt, T., and Mitchison, N.A. (2001). Tolerance and autoimmunity. N Engl J Med 
344, 655-664. 
Kang, J.Y., and Lee, J.O. (2011). Structural biology of the Toll-like receptor family. 
Annu Rev Biochem 80, 917-941. 
Karlsson, M.C., Guinamard, R., Bolland, S., Sankala, M., Steinman, R.M., and 
Ravetch, J.V. (2003). Macrophages control the retention and trafficking of B 
lymphocytes in the splenic marginal zone. J Exp Med 198, 333-340. 
Kawai, T., and Akira, S. (2011). Toll-like receptors and their crosstalk with other innate 
receptors in infection and immunity. Immunity 34, 637-650. 
Khamas, A., Ishikawa, T., Shimokawa, K., Mogushi, K., Iida, S., Ishiguro, M., 
Mizushima, H., Tanaka, H., Uetake, H., and Sugihara, K. (2012). Screening for 
epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, 
microarray and gene expression profile. Cancer Genomics Proteomics 9, 67-75. 
Kishore, U., Greenhough, T.J., Waters, P., Shrive, A.K., Ghai, R., Kamran, M.F., 
Bernal, A.L., Reid, K.B., Madan, T., and Chakraborty, T. (2006). Surfactant 
proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 43, 
1293-1315. 
Kodama, T., Freeman, M., Rohrer, L., Zabrecky, J., Matsudaira, P., and Krieger, M. 
(1990). Type I macrophage scavenger receptor contains alpha-helical and 
collagen-like coiled coils. Nature 343, 531-535. 
  42 
Krieger, M., and Herz, J. (1994). Structures and functions of multiligand lipoprotein 
receptors: macrophage scavenger receptors and LDL receptor-related protein 
(LRP). Annu Rev Biochem 63, 601-637. 
Lee, P.L., Gaasterland, T., and Barton, J.C. (2012). Mild iron overload in an African 
American man with SLC40A1 D270V. Acta Haematol 128, 28-32. 
Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., and Hoffmann, J.A. (1996). The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent 
antifungal response in Drosophila adults. Cell 86, 973-983. 
Levy, S.B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes, 
challenges and responses. Nat Med 10, S122-129. 
Levy-Barazany, H., and Frenkel, D. (2012). Expression of scavenger receptor A on 
antigen presenting cells is important for CD4+ T-cells proliferation in EAE 
mouse model. J Neuroinflammation 9, 120. 
Li, J.Y., Paragas, N., Ned, R.M., Qiu, A., Viltard, M., Leete, T., Drexler, I.R., Chen, X., 
Sanna-Cherchi, S., Mohammed, F., et al. (2009). Scara5 is a ferritin receptor 
mediating non-transferrin iron delivery. Dev Cell 16, 35-46. 
Limmon, G.V., Arredouani, M., McCann, K.L., Corn Minor, R.A., Kobzik, L., and 
Imani, F. (2008). Scavenger receptor class-A is a novel cell surface receptor for 
double-stranded RNA. FASEB J 22, 159-167. 
Louie, G.V., Yang, W., Bowman, M.E., and Choe, S. (1997). Crystal structure of the 
complex of diphtheria toxin with an extracellular fragment of its receptor. Mol 
Cell 1, 67-78. 
Madden, D.R. (1995). The three-dimensional structure of peptide-MHC complexes. 
Annu Rev Immunol 13, 587-622. 
Makinen, P.I., Lappalainen, J.P., Heinonen, S.E., Leppanen, P., Lahteenvuo, M.T., 
Aarnio, J.V., Heikkila, J., Turunen, M.P., and Yla-Herttuala, S. (2010). Silencing 
of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and 
reveals reciprocal upregulation of these receptors. Cardiovasc Res 88, 530-538. 
Manning-Tobin, J.J., Moore, K.J., Seimon, T.A., Bell, S.A., Sharuk, M., Alvarez-Leite, 
J.I., de Winther, M.P., Tabas, I., and Freeman, M.W. (2009). Loss of SR-A and 
CD36 activity reduces atherosclerotic lesion complexity without abrogating foam 
cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 29, 19-26. 
Martinez, V.G., Moestrup, S.K., Holmskov, U., Mollenhauer, J., and Lozano, F. 
(2011). The conserved scavenger receptor cysteine-rich superfamily in therapy 
and diagnosis. Pharmacol Rev 63, 967-1000. 
McGaha, T.L., Chen, Y., Ravishankar, B., van Rooijen, N., and Karlsson, M.C. (2011). 
Marginal zone macrophages suppress innate and adaptive immunity to apoptotic 
cells in the spleen. Blood 117, 5403-5412. 
Meri, S. (2007). Loss of self-control in the complement system and innate 
autoreactivity. Ann N Y Acad Sci 1109, 93-105. 
Miner, J.H., and Yurchenco, P.D. (2004). Laminin functions in tissue morphogenesis. 
Annu Rev Cell Dev Biol 20, 255-284. 
Monroe, J.G., Bannish, G., Fuentes-Panana, E.M., King, L.B., Sandel, P.C., Chung, J., 
and Sater, R. (2003). Positive and negative selection during B lymphocyte 
development. Immunol Res 27, 427-442. 
Moore, K.J., Kunjathoor, V.V., Koehn, S.L., Manning, J.J., Tseng, A.A., Silver, J.M., 
McKee, M., and Freeman, M.W. (2005). Loss of receptor-mediated lipid uptake 
via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis 
in hyperlipidemic mice. J Clin Invest 115, 2192-2201. 
Mukhopadhyay, S., Peiser, L., and Gordon, S. (2004). Activation of murine 
macrophages by Neisseria meningitidis and IFN-gamma in vitro: distinct roles of 
  43 
class A scavenger and Toll-like pattern recognition receptors in selective 
modulation of surface phenotype. J Leukoc Biol 76, 577-584. 
Mukhopadhyay, S., Varin, A., Chen, Y., Liu, B., Tryggvason, K., and Gordon, S. 
(2011). SR-A/MARCO-mediated ligand delivery enhances intracellular TLR and 
NLR function, but ligand scavenging from cell surface limits TLR4 response to 
pathogens. Blood 117, 1319-1328. 
Nakamura, K., Funakoshi, H., Miyamoto, K., Tokunaga, F., and Nakamura, T. (2001). 
Molecular cloning and functional characterization of a human scavenger receptor 
with C-type lectin (SRCL), a novel member of a scavenger receptor family. 
Biochem Biophys Res Commun 280, 1028-1035. 
Neyen, C., Pluddemann, A., Roversi, P., Thomas, B., Cai, L., van der Westhuyzen, 
D.R., Sim, R.B., and Gordon, S. (2009). Macrophage scavenger receptor A 
mediates adhesion to apolipoproteins A-I and E. Biochemistry 48, 11858-11871. 
Ohnishi, K., Komohara, Y., Fujiwara, Y., Takemura, K., Lei, X., Nakagawa, T., 
Sakashita, N., and Takeya, M. (2011). Suppression of TLR4-mediated 
inflammatory response by macrophage class A scavenger receptor (CD204). 
Biochem Biophys Res Commun 411, 516-522. 
Ohtani, K., Suzuki, Y., Eda, S., Kawai, T., Kase, T., Keshi, H., Sakai, Y., Fukuoh, A., 
Sakamoto, T., Itabe, H., et al. (2001). The membrane-type collectin CL-P1 is a 
scavenger receptor on vascular endothelial cells. J Biol Chem 276, 44222-44228. 
Ohtani, K., Suzuki, Y., and Wakamiya, N. (2012). Biological functions of the novel 
collectins CL-L1, CL-K1, and CL-P1. J Biomed Biotechnol 2012, 493945. 
Olive, C. (2012). Pattern recognition receptors: sentinels in innate immunity and targets 
of new vaccine adjuvants. Expert Rev Vaccines 11, 237-256. 
Ozment, T.R., Ha, T., Breuel, K.F., Ford, T.R., Ferguson, D.A., Kalbfleisch, J., 
Schweitzer, J.B., Kelley, J.L., Li, C., and Williams, D.L. (2012). Scavenger 
receptor class a plays a central role in mediating mortality and the development 
of the pro-inflammatory phenotype in polymicrobial sepsis. PLoS Pathog 8, 
e1002967. 
Palecanda, A., Paulauskis, J., Al-Mutairi, E., Imrich, A., Qin, G., Suzuki, H., Kodama, 
T., Tryggvason, K., Koziel, H., and Kobzik, L. (1999). Role of the scavenger 
receptor MARCO in alveolar macrophage binding of unopsonized environmental 
particles. J Exp Med 189, 1497-1506. 
Pandey, S., and Agrawal, D.K. (2006). Immunobiology of Toll-like receptors: 
emerging trends. Immunol Cell Biol 84, 333-341. 
Patel, D.D., Wee, S.F., Whichard, L.P., Bowen, M.A., Pesando, J.M., Aruffo, A., and 
Haynes, B.F. (1995). Identification and characterization of a 100-kD ligand for 
CD6 on human thymic epithelial cells. J Exp Med 181, 1563-1568. 
Peiser, L., Gough, P.J., Kodama, T., and Gordon, S. (2000). Macrophage class A 
scavenger receptor-mediated phagocytosis of Escherichia coli: role of cell 
heterogeneity, microbial strain, and culture conditions in vitro. Infect Immun 68, 
1953-1963. 
Peiser, L., Makepeace, K., Pluddemann, A., Savino, S., Wright, J.C., Pizza, M., 
Rappuoli, R., Moxon, E.R., and Gordon, S. (2006). Identification of Neisseria 
meningitidis nonlipopolysaccharide ligands for class A macrophage scavenger 
receptor by using a novel assay. Infect Immun 74, 5191-5199. 
Peiser, L., Mukhopadhyay, S., and Gordon, S. (2002). Scavenger receptors in innate 
immunity. Curr Opin Immunol 14, 123-128. 
Pikkarainen, T., Brannstrom, A., and Tryggvason, K. (1999). Expression of 
macrophage MARCO receptor induces formation of dendritic plasma membrane 
processes. J Biol Chem 274, 10975-10982. 
  44 
Platt, N., Suzuki, H., Kurihara, Y., Kodama, T., and Gordon, S. (1996). Role for the 
class A macrophage scavenger receptor in the phagocytosis of apoptotic 
thymocytes in vitro. Proc Natl Acad Sci U S A 93, 12456-12460. 
Pluddemann, A., Hoe, J.C., Makepeace, K., Moxon, E.R., and Gordon, S. (2009). The 
macrophage scavenger receptor A is host-protective in experimental 
meningococcal septicaemia. PLoS Pathog 5, e1000297. 
Pluddemann, A., Mukhopadhyay, S., and Gordon, S. (2006). The interaction of 
macrophage receptors with bacterial ligands. Expert Rev Mol Med 8, 1-25. 
Rast, J.P., Smith, L.C., Loza-Coll, M., Hibino, T., and Litman, G.W. (2006). Genomic 
insights into the immune system of the sea urchin. Science 314, 952-956. 
Raycroft, M.T., Harvey, B.P., Bruck, M.J., and Mamula, M.J. (2012). Inhibition of 
antigen trafficking through scavenger receptor A. J Biol Chem 287, 5310-5316. 
Resnick, D., Chatterton, J.E., Schwartz, K., Slayter, H., and Krieger, M. (1996). 
Structures of class A macrophage scavenger receptors. Electron microscopic 
study of flexible, multidomain, fibrous proteins and determination of the disulfide 
bond pattern of the scavenger receptor cysteine-rich domain. J Biol Chem 271, 
26924-26930. 
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key 
system for immune surveillance and homeostasis. Nat Immunol 11, 785-797. 
Rodamilans, B., Munoz, I.G., Bragado-Nilsson, E., Sarrias, M.R., Padilla, O., Blanco, 
F.J., Lozano, F., and Montoya, G. (2007). Crystal structure of the third 
extracellular domain of CD5 reveals the fold of a group B scavenger cysteine-
rich receptor domain. J Biol Chem 282, 12669-12677. 
Rogers, N.J., Lees, M.J., Gabriel, L., Maniati, E., Rose, S.J., Potter, P.K., and Morley, 
B.J. (2009). A defect in Marco expression contributes to systemic lupus 
erythematosus development via failure to clear apoptotic cells. J Immunol 182, 
1982-1990. 
Roozendaal, R., and Mebius, R.E. (2011). Stromal cell-immune cell interactions. Annu 
Rev Immunol 29, 23-43. 
Sakaguchi, H., Takeya, M., Suzuki, H., Hakamata, H., Kodama, T., Horiuchi, S., 
Gordon, S., van der Laan, L.J., Kraal, G., Ishibashi, S., et al. (1998). Role of 
macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab 
Invest 78, 423-434. 
Samsen, A., Bogoevska, V., Klampe, B., Bamberger, A.M., Lucka, L., Horst, A.K., 
Nollau, P., and Wagener, C. (2010). DC-SIGN and SRCL bind glycans of 
carcinoembryonic antigen (CEA) and CEA-related cell adhesion molecule 1 
(CEACAM1): recombinant human glycan-binding receptors as analytical tools. 
Eur J Cell Biol 89, 87-94. 
Sankala, M., Brannstrom, A., Schulthess, T., Bergmann, U., Morgunova, E., Engel, J., 
Tryggvason, K., and Pikkarainen, T. (2002). Characterization of recombinant 
soluble macrophage scavenger receptor MARCO. J Biol Chem 277, 33378-
33385. 
Sarraj, M.A., McClive, P.J., Wilmore, H.P., Loveland, K.L., and Sinclair, A.H. (2005). 
Novel scavenger receptor gene is differentially expressed in the embryonic and 
adult mouse testis. Dev Dyn 234, 1026-1033. 
Sarrias, M.R., Gronlund, J., Padilla, O., Madsen, J., Holmskov, U., and Lozano, F. 
(2004). The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and 
highly conserved protein module of the innate immune system. Crit Rev 
Immunol 24, 1-37. 
Sarrias, M.R., Rosello, S., Sanchez-Barbero, F., Sierra, J.M., Vila, J., Yelamos, J., 
Vives, J., Casals, C., and Lozano, F. (2005). A role for human Sp alpha as a 
pattern recognition receptor. J Biol Chem 280, 35391-35398. 
  45 
Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M.F., and Ohashi, P.S. 
(1999). Selection of the T cell repertoire. Annu Rev Immunol 17, 829-874. 
Selman, L., Skjodt, K., Nielsen, O., Floridon, C., Holmskov, U., and Hansen, S. (2008). 
Expression and tissue localization of collectin placenta 1 (CL-P1, SRCL) in 
human tissues. Mol Immunol 45, 3278-3288. 
Seta, N., Granfors, K., Sahly, H., Kuipers, J.G., Song, Y.W., Baeten, D., Veys, E.M., 
Maksymowych, W., Marker-Hermann, E., Gu, J., et al. (2001). Expression of 
host defense scavenger receptors in spondylarthropathy. Arthritis Rheum 44, 
931-939. 
Sleiman, R.J., Gray, P.P., McCall, M.N., Codamo, J., and Sunstrom, N.A. (2008). 
Accelerated cell line development using two-color fluorescence activated cell 
sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 
99, 578-587. 
Somoza, J.R., Ho, J.D., Luong, C., Ghate, M., Sprengeler, P.A., Mortara, K., Shrader, 
W.D., Sperandio, D., Chan, H., McGrath, M.E., et al. (2003). The structure of the 
extracellular region of human hepsin reveals a serine protease domain and a 
novel scavenger receptor cysteine-rich (SRCR) domain. Structure 11, 1123-1131. 
Sorrell, J.M., and Caplan, A.I. (2009). Fibroblasts-a diverse population at the center of 
it all. Int Rev Cell Mol Biol 276, 161-214. 
Stanietsky, N., and Mandelboim, O. (2010). Paired NK cell receptors controlling NK 
cytotoxicity. FEBS Lett 584, 4895-4900. 
Suniara, R.K., Jenkinson, E.J., and Owen, J.J. (2000). An essential role for thymic 
mesenchyme in early T cell development. J Exp Med 191, 1051-1056. 
Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., Ueda, O., 
Sakaguchi, H., Higashi, T., Suzuki, T., et al. (1997). A role for macrophage 
scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386, 
292-296. 
Szmitko, P.E., Wang, C.H., Weisel, R.D., de Almeida, J.R., Anderson, T.J., and Verma, 
S. (2003). New markers of inflammation and endothelial cell activation: Part I. 
Circulation 108, 1917-1923. 
Thelen, T., Hao, Y., Medeiros, A.I., Curtis, J.L., Serezani, C.H., Kobzik, L., Harris, 
L.H., and Aronoff, D.M. (2010). The class A scavenger receptor, macrophage 
receptor with collagenous structure, is the major phagocytic receptor for 
Clostridium sordellii expressed by human decidual macrophages. J Immunol 185, 
4328-4335. 
Thomas, C.A., Li, Y., Kodama, T., Suzuki, H., Silverstein, S.C., and El Khoury, J. 
(2000). Protection from lethal gram-positive infection by macrophage scavenger 
receptor-dependent phagocytosis. J Exp Med 191, 147-156. 
Tian, L., Humblet-Baron, S., and Liston, A. (2012). Immune tolerance: are regulatory T 
cell subsets needed to explain suppression of autoimmunity? Bioessays 34, 569-
575. 
Turvey, S.E., and Broide, D.H. (2010). Innate immunity. J Allergy Clin Immunol 125, 
S24-32. 
Uthaisangsook, S., Day, N.K., Bahna, S.L., Good, R.A., and Haraguchi, S. (2002). 
Innate immunity and its role against infections. Ann Allergy Asthma Immunol 
88, 253-264; quiz 265-256, 318. 
van den Elsen, J.M., Martin, A., Wong, V., Clemenza, L., Rose, D.R., and Isenman, 
D.E. (2002). X-ray crystal structure of the C4d fragment of human complement 
component C4. J Mol Biol 322, 1103-1115. 
van der Laan, L.J., Dopp, E.A., Haworth, R., Pikkarainen, T., Kangas, M., Elomaa, O., 
Dijkstra, C.D., Gordon, S., Tryggvason, K., and Kraal, G. (1999). Regulation and 
  46 
functional involvement of macrophage scavenger receptor MARCO in clearance 
of bacteria in vivo. J Immunol 162, 939-947. 
van der Laan, L.J., Kangas, M., Dopp, E.A., Broug-Holub, E., Elomaa, O., Tryggvason, 
K., and Kraal, G. (1997). Macrophage scavenger receptor MARCO: in vitro and 
in vivo regulation and involvement in the anti-bacterial host defense. Immunol 
Lett 57, 203-208. 
Vogel, J.D., West, G.A., Danese, S., De La Motte, C., Phillips, M.H., Strong, S.A., 
Willis, J., and Fiocchi, C. (2004). CD40-mediated immune-nonimmune cell 
interactions induce mucosal fibroblast chemokines leading to T-cell 
transmigration. Gastroenterology 126, 63-80. 
Wermeling, F., Chen, Y., Pikkarainen, T., Scheynius, A., Winqvist, O., Izui, S., 
Ravetch, J.V., Tryggvason, K., and Karlsson, M.C. (2007). Class A scavenger 
receptors regulate tolerance against apoptotic cells, and autoantibodies against 
these receptors are predictive of systemic lupus. J Exp Med 204, 2259-2265. 
West, A.P., Koblansky, A.A., and Ghosh, S. (2006). Recognition and signaling by toll-
like receptors. Annu Rev Cell Dev Biol 22, 409-437. 
Yan, N., Zhang, S., Yang, Y., Cheng, L., Li, C., Dai, L., Zhang, X., Fan, P., Tian, H., 
Wang, R., et al. (2012). Therapeutic upregulation of Class A scavenger receptor 
member 5 inhibits tumor growth and metastasis. Cancer Sci 103, 1631-1639. 
Yew, K.H., Carsten, B., and Harrison, C. (2010). Scavenger receptor A1 is required for 
sensing HCMV by endosomal TLR-3/-9 in monocytic THP-1 cells. Mol 
Immunol 47, 883-893. 
Yoshida, T., Tsuruta, Y., Iwasaki, M., Yamane, S., Ochi, T., and Suzuki, R. (2003). 
SRCL/CL-P1 recognizes GalNAc and a carcinoma-associated antigen, Tn 
antigen. J Biochem 133, 271-277. 
Yu, G., Tseng, G.C., Yu, Y.P., Gavel, T., Nelson, J., Wells, A., Michalopoulos, G., 
Kokkinakis, D., and Luo, J.H. (2006). CSR1 suppresses tumor growth and 
metastasis of prostate cancer. Am J Pathol 168, 597-607. 
Zelensky, A.N., and Gready, J.E. (2005). The C-type lectin-like domain superfamily. 
FEBS J 272, 6179-6217. 
Zheng, Z.L., Tan, L.Z., Yu, Y.P., Michalopoulos, G., and Luo, J.H. (2012). Interaction 
of CSR1 with XIAP reverses inhibition of caspases and accelerates cell death. 
Am J Pathol 181, 463-471. 
Zhu, F.G., Reich, C.F., and Pisetsky, D.S. (2001). The role of the macrophage 
scavenger receptor in immune stimulation by bacterial DNA and synthetic 
oligonucleotides. Immunology 103, 226-234. 
Zhu, Z.H., Yu, Y.P., Shi, Y.K., Nelson, J.B., and Luo, J.H. (2009). CSR1 induces cell 
death through inactivation of CPSF3. Oncogene 28, 41-51. 
Zuo, D., Yu, X., Guo, C., Wang, H., Qian, J., Yi, H., Lu, X., Lv, Z.P., Subjeck, J.R., 
Zhou, H., et al. (2013). Scavenger receptor a restrains T-cell activation and 
protects against concanavalin A-induced hepatic injury. Hepatology 57, 228-238. 
 
 
